Skip to content
← All treatment topics

TREATMENT READING

Central Nervous System Tumors

Source sections for this topic, with the original link and date. Patient and professional reading are labelled separately.

Not medical advice · Not a complete treatment or trial directory

Made by Triangle.

Selected text from the National Cancer Institute, with the original link and date. Made by Triangle. This page is not an NCI PDQ summary. Source topics may be broader than an individual diagnosis.

81 sections
  1. Treatment Option Overview for Primary CNS Tumors
  2. Primary CNS Tumors
  3. Surgery
  4. Radiation therapy
  5. High-grade tumors
  6. Low-grade tumors
  7. Disease progression, subsequent neoplasms, or recurrences
  8. Chemotherapy
  9. Systemic chemotherapy
  10. Localized chemotherapy (carmustine wafer)
  11. Active surveillance
  12. Supportive therapy
  13. Treatment of Primary CNS Tumors by Tumor Type
  14. Astrocytic Tumors Treatment
  15. Brain stem gliomas treatment
  16. Pineal astrocytic tumors treatment
  17. Pilocytic astrocytomas treatment
  18. Diffuse astrocytomas treatment
  19. Anaplastic astrocytomas treatment
  20. Glioblastomas treatment
  21. Oligodendroglial Tumors Treatment
  22. Oligodendrogliomas treatment
  23. Anaplastic oligodendrogliomas treatment
  24. Mixed Gliomas Treatment
  25. Ependymal Tumors Treatment
  26. Embryonal Cell Tumors (Medulloblastomas) Treatment
  27. Pineal Parenchymal Tumors Treatment
  28. Meningeal Tumors Treatment
  29. Germ Cell Tumors Treatment
  30. Treatment of Tumors of the Sellar Region
  31. Treatment Options Under Clinical Evaluation for Primary CNS Tumors
  32. Treatment of Primary Tumors of the Spinal Axis
  33. Treatment of Metastatic Brain Tumors
  34. Treatment for patients with one to four metastases
  35. Treatment options for patients with one to four metastases
  36. Treatment of Recurrent CNS Tumors
  37. Chemotherapy
  38. Localized chemotherapy (carmustine wafer)
  39. Systemic chemotherapy
  40. Antiangiogenesis Therapy
  41. Radiation Therapy
  42. Surgery
  43. Certain factors affect prognosis (chance of recovery) and treatment options.
  44. Imaging tests may be repeated after surgery to help plan more treatment.
  45. Central nervous system (CNS) tumors often recur, sometimes many years after treatment.
  46. Treatment Option Overview
  47. Key Points
  48. There are different types of treatment for patients with adult brain and spinal cord tumors.
  49. The following types of treatment are used:
  50. Active surveillance
  51. Surgery
  52. Radiation therapy
  53. Chemotherapy
  54. Targeted therapy
  55. Supportive care is given to lessen the problems caused by the disease or its treatment.
  56. New types of treatment are being tested in clinical trials.
  57. Proton beam radiation therapy
  58. Immunotherapy
  59. Treatment for adult central nervous system tumors may cause side effects.
  60. Patients may want to think about taking part in a clinical trial.
  61. Patients can enter clinical trials before, during, or after starting their cancer treatment.
  62. Follow-up tests may be needed.
  63. Treatment of Primary Adult Brain Tumor by Type of Tumor
  64. Astrocytic Tumors
  65. Brain Stem Gliomas
  66. Pineal Astrocytic Tumors
  67. Pilocytic Astrocytomas
  68. Diffuse Astrocytomas
  69. Anaplastic Astrocytomas
  70. Glioblastomas
  71. Oligodendroglial Tumors
  72. Mixed Gliomas
  73. Ependymal Tumors
  74. Medulloblastomas
  75. Pineal Parenchymal Tumors
  76. Meningeal Tumors
  77. Germ Cell Tumors
  78. Craniopharyngiomas
  79. Treatment of Primary Adult Spinal Cord Tumors
  80. Treatment of Recurrent Adult Central Nervous System Tumors
  81. Treatment of Metastatic Adult Brain Tumors

Health professional

Treatment Option Overview for Primary CNS Tumors

Source: Central Nervous System Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: March 28, 2025. Captured 2026-09-09.

Health professional · Treatment Option Overview for Primary CNS Tumors

Primary CNS Tumors

Source: Central Nervous System Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: March 28, 2025. Captured 2026-09-09.

This section discusses general treatment modalities for primary central nervous system (CNS) tumors. For a description of specific treatment options for each tumor type, see the Treatment of Primary CNS Tumors by Tumor Type section.

Sources: Treatment of Primary CNS Tumors by Tumor Type

Radiation therapy and chemotherapy options vary according to histology and anatomical site of the CNS tumor. For glioblastoma, combined-modality therapy with resection, radiation, and chemotherapy is standard. Anaplastic astrocytomas, anaplastic oligodendrogliomas, and anaplastic oligoastrocytomas represent only a small proportion of CNS gliomas. Therefore, phase III randomized trials restricted to these tumor types are not generally practical. The natural histories of these tumors are variable, depending on histological and molecular factors; therefore, treatment guidelines for these tumors are evolving. Therapy involving surgically implanted carmustine-impregnated polymer wafers combined with postoperative external-beam radiation therapy (EBRT) may play a role in the treatment of high-grade (grades III and IV) gliomas in some patients.[1]

Sources: 1

Treatment options for primary CNS tumors include:

Surgery.

Sources: Surgery

Radiation therapy.

Sources: Radiation therapy

Chemotherapy.

Sources: Chemotherapy

Active surveillance.

Sources: Active surveillance

Supportive therapy.

Sources: Supportive therapy

This page is made by Triangle. The reading above is selected source text, not a treatment recommendation, and it is not medical advice.

Health professional · Treatment Option Overview for Primary CNS Tumors / Primary CNS Tumors

Surgery

Source: Central Nervous System Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: March 28, 2025. Captured 2026-09-09.

For most types of CNS tumors in most locations, complete or near-complete surgical removal is generally attempted, within the constraints of preserving neurological function and the patient's underlying health. This practice is based on observational evidence that survival is better in patients who undergo tumor resection than in those who have closed biopsy alone.[2,3] The benefit of resection has not been tested in randomized trials. Selection bias can enter into observational studies despite attempts to adjust for patient differences that guide the decision to resect the tumor. Therefore, the actual difference in outcome between radical surgery and biopsy alone may not be as large as noted in the retrospective studies.[3]

Sources: 2 · 3 · 3

An exception to the use of resection is the case of deep-seated tumors such as pontine gliomas, which are diagnosed on clinical evidence and treated without initial surgery approximately 50% of the time. In most cases, however, diagnosis by biopsy is preferred. Stereotactic biopsy can be used for lesions that are difficult to reach and resect.

The primary goals of surgical resection include:[4]

Sources: 4

To establish a histological diagnosis.

To reduce intracranial pressure by removing as much tumor as is safely possible to preserve neurological function.

Total elimination of primary malignant intraparenchymal tumors by surgery alone is rarely achievable. Therefore, intraoperative techniques have been developed to reach a balance between removing as much tumor as is practical and preserving functional status. For example, craniotomies with stereotactic resections of primary gliomas can be performed in cooperative patients while they are awake, with real-time assessment of neurological function.[5] Examples of intraoperative neurological assessment include:

Sources: 5

Resection proceeds until either the magnetic resonance imaging (MRI) signal abnormality being used to monitor the extent of surgery is completely removed or subtle neurological dysfunction appears (e.g., a slight decrease in rapid alternating motor movement or anomia).

When the tumor is located in or near language centers in the cortex, intraoperative language mapping can be performed by electrode discharge-induced speech arrest while the patient is asked to count or read.[6]

Sources: 6

As is the case with several other specialized operations [7,8] in which postoperative mortality has been associated with the number of procedures performed, postoperative mortality after surgery for primary brain tumors may be associated with hospital and/or surgeon volume.[9] The following results were reported after an analysis of the Nationwide Inpatient Sample hospital discharge database for the years 1988 to 2000, which represented 20% of inpatient admissions to nonfederal U.S. hospitals:[9]

Sources: 7 · 8 · 9 · 9

Large-volume hospitals had lower in-hospital mortality rates after craniotomies for primary brain tumors (odds ratio [OR], 0.75 for a tenfold higher caseload; 95% confidence interval [CI], 0.62–0.90) and after needle biopsies (OR, 0.54; 95% CI, 0.35–0.83).

Although there was no specific sharp threshold in all-cause mortality outcomes between low-volume hospitals and high-volume hospitals, craniotomy-associated in-hospital mortality was 4.5% for hospitals with 5 or fewer procedures per year and 1.5% for hospitals with at least 42 procedures per year.

In-hospital mortality rates decreased over the study years (perhaps because the proportion of elective nonemergent operations increased from 45% to 57%), but the decrease was more rapid in high-volume hospitals than in low-volume hospitals.

High-volume surgeons had lower in-hospital patient mortality rates after craniotomy (OR, 0.60; 95% CI, 0.45–0.79).

As with any study of volume-outcome associations, these results may not be causal because of residual confounding factors such as referral patterns, private insurance, and patient selection, despite multivariable adjustment.

Health professional · Treatment Option Overview for Primary CNS Tumors / Primary CNS Tumors

Radiation therapy

Source: Central Nervous System Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: March 28, 2025. Captured 2026-09-09.

Health professional · Treatment Option Overview for Primary CNS Tumors / Primary CNS Tumors / Radiation therapy

High-grade tumors

Source: Central Nervous System Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: March 28, 2025. Captured 2026-09-09.

Radiation therapy has a major role in the treatment of patients with high-grade gliomas.

Evidence (postoperative radiation therapy [PORT]):

A systematic review and meta-analysis of five randomized trials (plus one trial with allocation by birth date) comparing PORT with no radiation therapy showed a statistically significant survival advantage with radiation (risk ratio, 0.81; 95% CI, 0.74–0.88).[10][Level of evidence A1]

Sources: 10 · Level of evidence A1

A randomized trial comparing 60 Gy (in 30 fractions over 6 weeks) with 45 Gy (in 25 fractions over 4 weeks) showed superior survival in the first group (12 months vs. 9 months median survival; hazard ratio [HR], 0.81; 95% CI, 0.66–0.99). The accepted standard dose of EBRT for malignant gliomas is 60 Gy.[11][Level of evidence A1]

Sources: 11 · Level of evidence A1

EBRT using either 3-dimensional conformal radiation therapy (3D-CRT) or intensity-modulated radiation therapy (IMRT) is considered an acceptable technique in radiation therapy delivery. Typically used are 2- to 3-cm margins on the MRI-based volumes (T1-weighted and fluid-attenuated inversion recovery [FLAIR]) to create the planning target volume.

Dose escalation using radiosurgery has not improved outcomes. A randomized trial tested radiosurgery as a boost added to standard EBRT, but the trial found no improvement in survival, quality of life, or patterns of relapse compared with EBRT without the boost.[12,13]

Sources: 12 · 13

Brachytherapy has been used to deliver high doses of radiation locally to the tumor while sparing normal brain tissue. However, this approach is technically demanding and is less common since the advent of 3D-CRT and IMRT.

Health professional · Treatment Option Overview for Primary CNS Tumors / Primary CNS Tumors / Radiation therapy

Low-grade tumors

Source: Central Nervous System Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: March 28, 2025. Captured 2026-09-09.

Treatment options for patients with low-grade gliomas (i.e., low-grade astrocytomas, oligodendrogliomas, and mixed oligoastrocytomas) are not as clear as in the case of high-grade tumors and include observation, PORT, and chemotherapy with temozolomide.

Evidence (PORT vs. observation):

The European Organisation for Research and Treatment of Cancer (EORTC) randomly assigned 311 patients with low-grade gliomas to undergo either radiation or observation in the EORTC-22845 trial.[14,15] On review of central pathology, about 25% of patients in the trial were reported to have high-grade tumors. Most of the control patients received radiation therapy at the time of progression.

Sources: 14 · 15

The European Organisation for Research and Treatment of Cancer (EORTC) randomly assigned 311 patients with low-grade gliomas to undergo either radiation or observation in the EORTC-22845 trial.[14,15] On review of central pathology, about 25% of patients in the trial were reported to have high-grade tumors. Most of the control patients received radiation therapy at the time of progression.

After a median follow-up of 93 months, the median progression-free survival (PFS) was 5.3 years in the radiation arm versus 3.4 years in the control arm (HR, 0.59; 95% CI, 0.45–0.77).[14,15][Level of evidence B1]

Sources: 14 · 15 · Level of evidence B1

There was no difference in the overall survival (OS). The median survival was 7.4 years in the radiation arm and 7.2 years in the control arm (HR, 0.97; 95% CI, 0.71–1.34; P = .87).[14,15][Level of evidence A1] This was caused by a longer survival after progression in the control arm (3.4 years) than in the radiation arm (1.0 year) (P < .0001).

Sources: 14 · 15 · Level of evidence A1

The investigators did not collect reliable quality-of-life measurements, so it is not clear whether the delay in initial relapse in the radiation therapy arm translated into improved function or quality of life.

Evidence (PORT versus temozolomide for patients with low-grade World Health Organization [WHO] grade II tumors with at least one high-risk feature):

The EORTC 22033-26033 trial (NCT00182819) included 707 patients with low-grade glioma (WHO grade II astrocytoma, oligoastrocytoma, or oligodendroglioma) and at least one high-risk feature (age >40 years, progressive disease, tumor size >5 cm, tumor crossing the midline, or neurological symptoms). Patients were randomly assigned to receive either radiation therapy (n = 240) or temozolomide chemotherapy (n = 237). Radiation therapy consisted of conformal treatment (up to 50.4 Gy; 28 doses of 1.8 Gy daily, 5 days a week, for up to 6.5 weeks). Chemotherapy was dose-dense oral temozolomide (75 mg/m2 daily for 21 days, repeated every 28 days [one cycle], for a maximum of 12 cycles).[16,17]

Sources: EORTC 22033-26033 · 16 · 17

The EORTC 22033-26033 trial (NCT00182819) included 707 patients with low-grade glioma (WHO grade II astrocytoma, oligoastrocytoma, or oligodendroglioma) and at least one high-risk feature (age >40 years, progressive disease, tumor size >5 cm, tumor crossing the midline, or neurological symptoms). Patients were randomly assigned to receive either radiation therapy (n = 240) or temozolomide chemotherapy (n = 237). Radiation therapy consisted of conformal treatment (up to 50.4 Gy; 28 doses of 1.8 Gy daily, 5 days a week, for up to 6.5 weeks). Chemotherapy was dose-dense oral temozolomide (75 mg/m2 daily for 21 days, repeated every 28 days [one cycle], for a maximum of 12 cycles).[16,17]

There was no significant difference in PFS (primary end point) or health-related quality of life (secondary end point).

At a median follow-up of 48 months (interquartile range, 31–56), median PFS was 39 months (95% CI, 35–44) in the temozolomide group and 46 months (95% CI, 40–56) in the radiation therapy group (unadjusted HR, 1.16; 95% CI, 0.9–1.5; P = .22).[16][Level of evidence B1]

Sources: 16 · Level of evidence B1

An exploratory analysis of 318 molecularly defined patients found that patients with IDH gene variants without codeletion of 1p/19q displayed a significantly longer PFS when treated with radiation therapy (HR, 1.86; 95% CI, 1.21–2.87; log-rank P = .0043).

There were no significant treatment-dependent differences in PFS for patients with IDH variants with codeletion of 1p/19q and IDH wild-type tumors.

Patients with wild-type IDH tumors had the worst prognosis independent of treatment type.

Patients with IDH variants with codeletion of 1p/19q had the best prognosis.

The O6-methylguanine-DNA methyltransferase (MGMT) promoter status was methylated in the following cases:

The EORTC 22033-26033 trial (NCT00182819) included 707 patients with low-grade glioma (WHO grade II astrocytoma, oligoastrocytoma, or oligodendroglioma) and at least one high-risk feature (age >40 years, progressive disease, tumor size >5 cm, tumor crossing the midline, or neurological symptoms). Patients were randomly assigned to receive either radiation therapy (n = 240) or temozolomide chemotherapy (n = 237). Radiation therapy consisted of conformal treatment (up to 50.4 Gy; 28 doses of 1.8 Gy daily, 5 days a week, for up to 6.5 weeks). Chemotherapy was dose-dense oral temozolomide (75 mg/m2 daily for 21 days, repeated every 28 days [one cycle], for a maximum of 12 cycles).[16,17] › The O6-methylguanine-DNA methyltransferase (MGMT) promoter status was methylated in the following cases:

All IDH variants with codeletion of 1p/19q (45/45).

Sixty-two of 72 (86%) of the IDH variants without codeletion of 1p/19q.

Five of nine (56%) of the IDH wild-type cases.

Health professional · Treatment Option Overview for Primary CNS Tumors / Primary CNS Tumors / Radiation therapy

Disease progression, subsequent neoplasms, or recurrences

Source: Central Nervous System Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: March 28, 2025. Captured 2026-09-09.

There are no randomized trials to delineate the role of repeat radiation after disease progression or the development of radiation-induced cancers. The literature is limited to small retrospective case series, which makes interpretation difficult.[18] The decision to repeat radiation must be made carefully because of the risk of neurocognitive deficits and radiation-induced necrosis. One advantage of radiosurgery is the ability to deliver therapeutic doses to recurrent tumors that may require the re-irradiation of previously irradiated brain tissue beyond tolerable dose limits.

Sources: 18

Health professional · Treatment Option Overview for Primary CNS Tumors / Primary CNS Tumors

Chemotherapy

Source: Central Nervous System Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: March 28, 2025. Captured 2026-09-09.

Health professional · Treatment Option Overview for Primary CNS Tumors / Primary CNS Tumors / Chemotherapy

Systemic chemotherapy

Source: Central Nervous System Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: March 28, 2025. Captured 2026-09-09.

For many years, the nitrosourea carmustine ([bis-chloroethylnitrosourea] BCNU) was the standard chemotherapy agent added to surgery and radiation therapy for malignant gliomas, based on the Radiation Therapy Oncology Group's (RTOG's) randomized trial (RTOG-8302).[19][Level of evidence A1] A modest impact on survival with the use of nitrosourea-containing chemotherapy regimens for malignant gliomas was confirmed in a patient-level meta-analysis of 12 randomized trials (combined HRdeath, 0.85; 95% CI, 0.78–0.91).[20]

Sources: 19 · Level of evidence A1 · 20

A large multicenter trial (NCT00006353) of patients with glioblastoma, conducted by the EORTC-National Cancer Institute of Canada, reported a survival advantage with the use of temozolomide in addition to radiation therapy.[21,22][Level of evidence A1] Based on these results, the oral agent temozolomide has replaced BCNU as the standard systemic chemotherapy for malignant gliomas. For more information, see the Glioblastomas treatment section.

Sources: NCT00006353 · 21 · 22 · Level of evidence A1 · Glioblastomas treatment

Long-term results of randomized trials in high-risk, low-grade (WHO grade II) gliomas [23][Level of evidence A1] and anaplastic (WHO grade III) oligodendroglial tumors [24,25][Level of evidence A1] have demonstrated that the addition of procarbazine, lomustine, and vincristine (PCV) chemotherapy to radiation therapy after surgery extends survival. Radiation and PCV chemotherapy should be considered for patients deemed appropriate for therapy. For more information, see the Treatment of Primary CNS Tumors by Tumor Type section.

Sources: 23 · Level of evidence A1 · 24 · 25 · Level of evidence A1 · Treatment of Primary CNS Tumors by Tumor Type

Health professional · Treatment Option Overview for Primary CNS Tumors / Primary CNS Tumors / Chemotherapy / Systemic chemotherapy

Localized chemotherapy (carmustine wafer)

Source: Central Nervous System Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: March 28, 2025. Captured 2026-09-09.

The ability to give high doses of chemotherapy while avoiding systemic toxicity is desirable because malignant glioma–related deaths are usually due to uncontrolled intracranial disease rather than distant metastases. A biodegradable carmustine wafer has been developed for that purpose. The wafers contain 3.85% carmustine, and up to eight wafers are implanted into the tumor bed lining at the time of open resection, with an intended total dose of about 7.7 mg per wafer (61.6 mg maximum per patient) over a period of 2 to 3 weeks.

Two randomized placebo-controlled trials of this focal drug-delivery method have shown an OS advantage associated with the carmustine wafers versus radiation therapy alone. In both trials, the upper age limit for patients was 65 years.

Evidence (carmustine wafer):

A small trial was closed because of a lack of continued availability of the carmustine wafers after 32 patients with high-grade gliomas had been entered.[26]

Sources: 26

A small trial was closed because of a lack of continued availability of the carmustine wafers after 32 patients with high-grade gliomas had been entered.[26]

Although OS was better in the carmustine-wafer group (median 58.1 vs. 39.9 weeks; P = .012), there was an imbalance in the study arms (only 11 of 16 patients in the carmustine-wafer group vs. 16 of the 16 patients in the placebo-wafer group had grade IV glioblastoma tumors).

A multicenter study of 240 patients with primary malignant gliomas, 207 of whom had glioblastoma, was more informative.[27,28] At initial surgery, patients received either carmustine wafers or placebo wafers, followed by radiation therapy (55–60 Gy). Systemic therapy was not allowed until recurrence, except in the case of anaplastic oligodendrogliomas (n = 9). Unlike the initial trial, patient characteristics were well balanced between the study arms.

Sources: 27 · 28

A multicenter study of 240 patients with primary malignant gliomas, 207 of whom had glioblastoma, was more informative.[27,28] At initial surgery, patients received either carmustine wafers or placebo wafers, followed by radiation therapy (55–60 Gy). Systemic therapy was not allowed until recurrence, except in the case of anaplastic oligodendrogliomas (n = 9). Unlike the initial trial, patient characteristics were well balanced between the study arms.

Median survival in the two groups was 13.8 months in patients treated with carmustine wafers versus 11.6 months in placebo-treated patients (HR, 0.73; 95% CI, 0.56–0.96; P = .017).

A systematic review combining both studies [26-28] estimated an HR for overall mortality of 0.65; 95% CI, 0.48–0.86; P = .003.[29][Level of evidence A1]

Sources: 26 · 28 · 29 · Level of evidence A1

Health professional · Treatment Option Overview for Primary CNS Tumors / Primary CNS Tumors

Active surveillance

Source: Central Nervous System Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: March 28, 2025. Captured 2026-09-09.

Active surveillance is appropriate in some circumstances. With the increasing use of sensitive neuroimaging tools, detection of asymptomatic low-grade meningiomas has increased; most appear to show minimal growth and can often be safely observed, with therapy deferred until the detection of tumor growth or the development of symptoms.[30,31]

Sources: 30 · 31

Health professional · Treatment Option Overview for Primary CNS Tumors / Primary CNS Tumors

Supportive therapy

Source: Central Nervous System Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: March 28, 2025. Captured 2026-09-09.

Dexamethasone, mannitol, and furosemide are used to treat the peritumoral edema associated with brain tumors. The use of anticonvulsants is mandatory for patients with seizures.[4]

Sources: 4

Health professional

Treatment of Primary CNS Tumors by Tumor Type

Source: Central Nervous System Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: March 28, 2025. Captured 2026-09-09.

Table 2. Treatment of Primary Central Nervous System Tumors by Tumor Type
Tumor TypeTreatment Options
Astrocytic tumors:
—Brain stem gliomasRadiation therapy
—Pineal astrocytic tumorsSurgery plus radiation therapy
Surgery plus radiation therapy and chemotherapy for higher-grade tumors
—Pilocytic astrocytomasSurgery alone
Surgery followed by radiation therapy
—Diffuse astrocytomas (WHO grade II)Surgery with or without radiation therapy
Surgery followed by radiation therapy and chemotherapy
—Anaplastic astrocytomas (WHO grade III)Surgery plus radiation therapy with or without chemotherapy
Surgery plus chemotherapy
—GlioblastomasSurgery plus radiation therapy and chemotherapy
Surgery plus radiation therapy
Carmustine-impregnated polymer implant
Radiation therapy and concurrent chemotherapy
Oligodendroglial tumors:
—OligodendrogliomasSurgery with or without radiation therapy
Surgery with radiation therapy and chemotherapy
—Anaplastic oligodendrogliomasSurgery plus radiation therapy with or without chemotherapy
Mixed gliomasSurgery plus radiation therapy with or without chemotherapy
Ependymal tumors:
—Grades I and II ependymal tumorsSurgery alone
Surgery followed by radiation therapy
—Anaplastic ependymomaSurgery plus radiation therapy
Embryonal cell tumors:
—MedulloblastomasSurgery plus craniospinal radiation therapy
Pineal parenchymal tumorsSurgery plus radiation therapy (for pineocytoma)
Surgery plus radiation therapy and chemotherapy (for pineoblastoma)
Meningeal tumors:
—Grade I meningiomasActive surveillance with deferred treatment
Surgery
Stereotactic radiosurgery
Surgery plus radiation therapy
Fractionated radiation therapy
—Grades II and III meningiomas and hemangiopericytomasSurgery plus radiation therapy
Germ cell tumors:Depends on multiple factors
Tumors of the sellar region
—CraniopharyngiomasSurgery alone
Debulking surgery plus radiation therapy

Sources: Radiation therapy · Surgery plus radiation therapy · Surgery plus radiation therapy and chemotherapy for higher-grade tumors · Surgery alone · Surgery followed by radiation therapy · Surgery with or without radiation therapy · Surgery followed by radiation therapy and chemotherapy · Surgery plus radiation therapy with or without chemotherapy · Surgery plus chemotherapy · Surgery plus radiation therapy and chemotherapy · Surgery plus radiation therapy · Carmustine-impregnated polymer implant · Radiation therapy and concurrent chemotherapy · Surgery with or without radiation therapy · Surgery with radiation therapy and chemotherapy · Surgery plus radiation therapy with or without chemotherapy · Surgery plus radiation therapy with or without chemotherapy · Surgery alone · Surgery followed by radiation therapy · Surgery plus radiation therapy · Surgery plus craniospinal radiation therapy · Surgery plus radiation therapy · Surgery plus radiation therapy and chemotherapy · Active surveillance with deferred treatment · Surgery · Stereotactic radiosurgery · Surgery plus radiation therapy · Fractionated radiation therapy · Surgery plus radiation therapy · Depends on multiple factors · Surgery alone · Debulking surgery plus radiation therapy

Health professional · Treatment of Primary CNS Tumors by Tumor Type

Astrocytic Tumors Treatment

Source: Central Nervous System Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: March 28, 2025. Captured 2026-09-09.

Health professional · Treatment of Primary CNS Tumors by Tumor Type / Astrocytic Tumors Treatment

Brain stem gliomas treatment

Source: Central Nervous System Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: March 28, 2025. Captured 2026-09-09.

Patients with brain stem gliomas have relatively poor prognoses that correlate with histology (when biopsies are performed), location, and extent of tumor. The overall median survival time of patients in studies has been 44 to 74 weeks.

Treatment options for brain stem gliomas include:

Radiation therapy.

Health professional · Treatment of Primary CNS Tumors by Tumor Type / Astrocytic Tumors Treatment

Pineal astrocytic tumors treatment

Source: Central Nervous System Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: March 28, 2025. Captured 2026-09-09.

Depending on the degree of anaplasia, patients with pineal astrocytomas have variable prognoses. Patients with higher-grade tumors have worse prognoses.

Treatment options for pineal astrocytic tumors include:

Surgery plus radiation therapy for pineal astrocytoma.

Surgery plus radiation therapy and chemotherapy for higher-grade tumors.

Health professional · Treatment of Primary CNS Tumors by Tumor Type / Astrocytic Tumors Treatment

Pilocytic astrocytomas treatment

Source: Central Nervous System Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: March 28, 2025. Captured 2026-09-09.

This astrocytic tumor is classified as a World Health Organization (WHO) grade I tumor and is often curable.

Treatment options for pilocytic astrocytomas include:

Surgery alone if the tumor is totally resectable.

Surgery followed by radiation therapy to known or suspected residual tumor.

Health professional · Treatment of Primary CNS Tumors by Tumor Type / Astrocytic Tumors Treatment

Diffuse astrocytomas treatment

Source: Central Nervous System Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: March 28, 2025. Captured 2026-09-09.

This WHO grade II astrocytic tumor is less often curable than is a pilocytic astrocytoma.

Treatment options for diffuse astrocytomas (WHO grade II) include:

Surgery with or without radiation therapy.

Surgery followed by radiation therapy and chemotherapy.

Controversy exists about the timing of radiation therapy after surgery. For more information, see the Low-grade tumors section.

Sources: Low-grade tumors

Radiation therapy improved progression-free survival (PFS) in patients who received early radiation therapy in the European Organisation for Research and Treatment of Cancer (EORTC) EORTC-22845 trial. For more information, see the Oligodendrogliomas treatment section.[1][Level of evidence A1]

Sources: Oligodendrogliomas treatment · 1 · Level of evidence A1

In the same trial, there was no difference in overall survival (OS) between patients who had radiation therapy after surgery and those who were treated with radiation therapy at the time of progression.[1][Level of evidence A1]

Sources: 1 · Level of evidence A1

Some physicians use surgery alone if a patient has clinical factors that are considered low risk, such as age younger than 40 years and the lack of contrast enhancement on a computed tomography scan.[2]

Sources: 2

Evidence (surgery followed by radiation therapy and chemotherapy):

For patients with low-grade (WHO grade II) tumors, which are considered high risk, radiation therapy followed by six cycles of vincristine (PCV) chemotherapy is a recommended option. This recommendation is based on the long-term follow-up results of the Radiation Therapy Oncology Group's (RTOG's) 1986-initiated randomized trial (RTOG 9802 [NCT00003375]).[3][Level of evidence A1] In this trial, patients with high-risk, low-grade glioma, defined as patients aged 18 to 39 years with biopsy or subtotal resection, or patients aged 40 years or older, were randomly assigned to either 54 Gy of radiation therapy or radiation therapy followed by six cycles of PCV chemotherapy.

Sources: RTOG 9802 · 3 · Level of evidence A1

For patients with low-grade (WHO grade II) tumors, which are considered high risk, radiation therapy followed by six cycles of vincristine (PCV) chemotherapy is a recommended option. This recommendation is based on the long-term follow-up results of the Radiation Therapy Oncology Group's (RTOG's) 1986-initiated randomized trial (RTOG 9802 [NCT00003375]).[3][Level of evidence A1] In this trial, patients with high-risk, low-grade glioma, defined as patients aged 18 to 39 years with biopsy or subtotal resection, or patients aged 40 years or older, were randomly assigned to either 54 Gy of radiation therapy or radiation therapy followed by six cycles of PCV chemotherapy.

The addition of PCV to radiation therapy increased median PFS from 4.0 years to 10.4 years (hazard ratio [HR], 0.50; P = .002) and median OS from 7.8 years to 13.3 years (HR, 0.59; P = .03).

Notably, the RTOG 9802 study enrolled patients with a variety of tumors, including astrocytomas, oligodendrogliomas, and mixed oligoastrocytomas.

For patients with low-grade (WHO grade II) tumors, which are considered high risk, radiation therapy followed by six cycles of vincristine (PCV) chemotherapy is a recommended option. This recommendation is based on the long-term follow-up results of the Radiation Therapy Oncology Group's (RTOG's) 1986-initiated randomized trial (RTOG 9802 [NCT00003375]).[3][Level of evidence A1] In this trial, patients with high-risk, low-grade glioma, defined as patients aged 18 to 39 years with biopsy or subtotal resection, or patients aged 40 years or older, were randomly assigned to either 54 Gy of radiation therapy or radiation therapy followed by six cycles of PCV chemotherapy. › Notably, the RTOG 9802 study enrolled patients with a variety of tumors, including astrocytomas, oligodendrogliomas, and mixed oligoastrocytomas.

In a risk-adjusted multivariate analysis, patients treated with PCV and patients with an oligodendroglial histology had better survival outcomes. A subset analysis of histological type suggested that the addition of PCV mainly benefited patients with oligodendroglial tumors, although this data is yet to be validated.[4]

Sources: 4

Median OS for PCV versus the control arm was not reached versus 10.8 years for oligodendrogliomas (P = .008), 11.4 years versus 5.9 years for oligoastrocytomas (P = .05), and 7.7 years versus 4.4 years for astrocytomas (P = .31).

The discovery of the IDH1 and IDH2 variants in diffuse gliomas has greatly helped to identify patients with high-risk disease. Large retrospective studies have demonstrated that IDH1 and IDH2 variants are powerful independent prognostic factors for improved survival.[5-9] Most WHO grade II and III gliomas harbor IDH1 and IDH2 variants,[6,10,11] and, therefore, those variants should be included in the assessment of high risk. Molecular correlative data from the RTOG 98-02 trial, which would be informative about which patients benefited the most from the addition of PCV, have not been reported.

Sources: 5 · 9 · 6 · 10 · 11

Health professional · Treatment of Primary CNS Tumors by Tumor Type / Astrocytic Tumors Treatment

Anaplastic astrocytomas treatment

Source: Central Nervous System Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: March 28, 2025. Captured 2026-09-09.

Patients with anaplastic astrocytomas (WHO grade III) have a low cure rate with standard local treatment.

Treatment options for anaplastic astrocytomas include:

Surgery plus radiation therapy with or without chemotherapy.

Surgery plus chemotherapy.

A subset of anaplastic astrocytomas is aggressive; these tumors are frequently managed in the same way as glioblastomas, with surgery and radiation, and often with chemotherapy. However, the optimal treatment for these tumors is not established. Two phase III randomized trials restricted to patients with anaplastic gliomas (NCT00626990 and NCT00887146) are active, but efficacy data are not available. It is not known whether the improved survival of patients with chemotherapy-treated glioblastoma can be extrapolated to patients with anaplastic astrocytomas.

Sources: NCT00626990 · NCT00887146

IDH1 and IDH2 variants are present in 50% to 70% of anaplastic astrocytomas and are independently associated with significantly improved survival.[6,9] Assessment of IDH1 and IDH2 variant status may guide decisions about treatment options.

Sources: 6 · 9

Evidence (surgery plus radiation therapy or chemotherapy):

Postoperative radiation alone has been compared with postoperative chemotherapy alone in patients with anaplastic gliomas (i.e., 144 astrocytomas, 91 oligoastrocytomas, and 39 oligodendrogliomas), with crossover to the other modality at the time of tumor progression. Of the 139 patients randomly assigned to undergo radiation therapy, 135 were randomly assigned to receive chemotherapy, with a 32-week course of either PCV or single-agent temozolomide (2:1:1 randomization).[12][Levels of evidence A1 and B1]

Sources: 12 · A1 · B1

Postoperative radiation alone has been compared with postoperative chemotherapy alone in patients with anaplastic gliomas (i.e., 144 astrocytomas, 91 oligoastrocytomas, and 39 oligodendrogliomas), with crossover to the other modality at the time of tumor progression. Of the 139 patients randomly assigned to undergo radiation therapy, 135 were randomly assigned to receive chemotherapy, with a 32-week course of either PCV or single-agent temozolomide (2:1:1 randomization).[12][Levels of evidence A1 and B1]

The order of the modalities did not affect time-to-treatment failure (TTF) or OS.

Neither TTF nor OS differed across the treatment arms.

Patients with anaplastic astrocytomas are appropriate candidates for clinical trials designed to improve local control by adding newer forms of treatment to standard treatment. Information about ongoing clinical trials is available from the NCI website.

Sources: NCI website

Health professional · Treatment of Primary CNS Tumors by Tumor Type / Astrocytic Tumors Treatment

Glioblastomas treatment

Source: Central Nervous System Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: March 28, 2025. Captured 2026-09-09.

For patients with glioblastoma (WHO grade IV), the cure rate is very low with standard local treatment.

Methylation of the promoter of the MGMT DNA repair enzyme gene is an independent prognostic factor for improved survival in newly diagnosed glioblastoma.[13,14] MGMT promoter methylation and concomitant inactivation of the DNA repair enzyme activities may also predict for response to temozolomide chemotherapy.[13] However, the clinical data that MGMT promoter methylation is a predictive marker is less certain.

Sources: 13 · 14 · 13

Treatment options for patients with newly diagnosed glioblastoma include:

Surgery plus radiation therapy and chemotherapy.

Surgery plus radiation therapy.

Carmustine-impregnated polymer implanted during initial surgery.

Radiation therapy and concurrent chemotherapy.

The standard treatment for patients with newly diagnosed glioblastoma is surgery followed by concurrent radiation therapy and daily temozolomide, and then followed by six cycles of temozolomide. The addition of bevacizumab to radiation therapy and temozolomide did not improve OS.

Evidence (surgery plus radiation therapy and chemotherapy):

Standard therapy is based on a large, multicenter, randomized trial (NCT00006353) conducted by the EORTC and National Cancer Institute of Canada (NCIC). This trial reported a survival benefit with concurrent radiation therapy and temozolomide, compared with radiation therapy alone.[15,16][Level of evidence A1] In this study, 573 patients with glioblastoma were randomly assigned to receive standard radiation to the tumor volume with a 2- to 3-cm margin (60 Gy, 2 Gy per fraction, over 6 weeks) alone or with temozolomide (75 mg/m2 orally per day during radiation therapy for up to 49 days, followed by a 4-week break and then up to six cycles of five daily doses every 28 days at a dose of 150 mg/m2, increasing to 200 mg/m2 after the first cycle).

Sources: NCT00006353 · 15 · 16 · Level of evidence A1

Standard therapy is based on a large, multicenter, randomized trial (NCT00006353) conducted by the EORTC and National Cancer Institute of Canada (NCIC). This trial reported a survival benefit with concurrent radiation therapy and temozolomide, compared with radiation therapy alone.[15,16][Level of evidence A1] In this study, 573 patients with glioblastoma were randomly assigned to receive standard radiation to the tumor volume with a 2- to 3-cm margin (60 Gy, 2 Gy per fraction, over 6 weeks) alone or with temozolomide (75 mg/m2 orally per day during radiation therapy for up to 49 days, followed by a 4-week break and then up to six cycles of five daily doses every 28 days at a dose of 150 mg/m2, increasing to 200 mg/m2 after the first cycle).

OS was statistically significantly better in the combined radiation therapy–temozolomide group (HRdeath, 0.6; 95% confidence interval [CI], 0.5–0.7; OS rate at 3 years was 16.0% for the radiation therapy–temozolomide group vs. 4.4% in the radiation therapy–alone group).

A companion molecular correlation subset study to the EORTC-NCIC trial provided strong evidence that epigenetic silencing of the MGMT DNA-repair gene by promoter DNA methylation was associated with increased OS in patients with newly diagnosed glioblastoma.[13]

Sources: 13

Standard therapy is based on a large, multicenter, randomized trial (NCT00006353) conducted by the EORTC and National Cancer Institute of Canada (NCIC). This trial reported a survival benefit with concurrent radiation therapy and temozolomide, compared with radiation therapy alone.[15,16][Level of evidence A1] In this study, 573 patients with glioblastoma were randomly assigned to receive standard radiation to the tumor volume with a 2- to 3-cm margin (60 Gy, 2 Gy per fraction, over 6 weeks) alone or with temozolomide (75 mg/m2 orally per day during radiation therapy for up to 49 days, followed by a 4-week break and then up to six cycles of five daily doses every 28 days at a dose of 150 mg/m2, increasing to 200 mg/m2 after the first cycle). › A companion molecular correlation subset study to the EORTC-NCIC trial provided strong evidence that epigenetic silencing of the MGMT DNA-repair gene by promoter DNA methylation was associated with increased OS in patients with newly diagnosed glioblastoma.[13]

MGMT promoter methylation was an independent favorable prognostic factor (HR, 0.45; 95% CI, 0.32–0.61; log-rank P < .001).

The median OS for patients with MGMT methylation was 18.2 months (95% CI, 15.5–22.0), compared with 12.2 months (95% CI, 11.4–13.5) for patients without MGMT methylation.

To test whether protracted (dose-dense) temozolomide enhances treatment response in patients with newly diagnosed glioblastoma, a multicenter, randomized, phase III trial conducted by the RTOG, EORTC, and the North Central Cancer Therapy Group, RTOG 0525 (NCT00304031), compared standard adjuvant temozolomide treatment (days 1–5 of a 28-day cycle) with a dose-dense schedule (days 1–21 of a 28-day cycle). All patients were treated with surgery followed by radiation therapy and concurrent daily temozolomide. Patients were then randomly assigned to receive either standard adjuvant temozolomide or dose-dense temozolomide.[14][Level of evidence A1]

Sources: RTOG 0525 · 14 · Level of evidence A1

To test whether protracted (dose-dense) temozolomide enhances treatment response in patients with newly diagnosed glioblastoma, a multicenter, randomized, phase III trial conducted by the RTOG, EORTC, and the North Central Cancer Therapy Group, RTOG 0525 (NCT00304031), compared standard adjuvant temozolomide treatment (days 1–5 of a 28-day cycle) with a dose-dense schedule (days 1–21 of a 28-day cycle). All patients were treated with surgery followed by radiation therapy and concurrent daily temozolomide. Patients were then randomly assigned to receive either standard adjuvant temozolomide or dose-dense temozolomide.[14][Level of evidence A1]

Among 833 randomly assigned patients, no statistically significant difference between standard and dose-dense temozolomide was observed for median OS (16.6 months for standard temozolomide vs. 14.9 months for dose-dense temozolomide; HR, 1.03; P = .63) or for median PFS (5.5 vs. 6.7 months; HR, 0.87; P = .06).

Protracted temozolomide, which depletes intracellular MGMT, was predicted to have greater efficacy in tumors with MGMT-promoter methylation. To test this retrospectively, MGMT status was determined in 86% of randomly assigned patients. No difference in efficacy was observed in either the MGMT-methylated or MGMT-unmethylated subsets. There was no survival advantage for the use of dose-dense temozolomide versus standard-dose temozolomide in newly diagnosed glioblastoma patients, regardless of MGMT status. However, this study confirmed the strong prognostic effect of MGMT methylation because the median OS was 21.2 months (95% CI, 17.9–24.8) for patients with methylation versus 14 months (HR, 1.74; 95% CI, 12.9–14.7; P < .001) for patients without methylation.

The efficacy of dose-dense temozolomide for patients who have recurrent glioblastoma, however, is yet to be determined.

Evidence (surgery and chemoradiation therapy with or without bevacizumab):

In 2013, final data from two multicenter, phase III, randomized, double-blind, placebo-controlled trials of bevacizumab in patients who had newly diagnosed glioblastoma were reported: RTOG 0825 (NCT00884741) and the Roche-sponsored AVAglio (NCT00943826).[17,18][Level of evidence A1] Bevacizumab did not improve OS in either trial.

Sources: RTOG 0825 · AVAglio · 17 · 18 · Level of evidence A1

There was significant crossover in both trials. Approximately 40% of RTOG 0825 patients and approximately 30% of AVAglio patients received bevacizumab at the first sign of disease progression.

RTOG 0825 (NCT00884741): Patients were randomly assigned to receive standard therapy (chemoradiation therapy with temozolomide) or standard therapy plus bevacizumab. OS and PFS were coprimary end points.[17][Level of evidence A1]

Sources: RTOG 0825 · 17 · Level of evidence A1

RTOG 0825 (NCT00884741): Patients were randomly assigned to receive standard therapy (chemoradiation therapy with temozolomide) or standard therapy plus bevacizumab. OS and PFS were coprimary end points.[17][Level of evidence A1]

Bevacizumab did not improve OS (median OS was 16–17 months for each arm). However, it increased median PFS (10.7 months in the bevacizumab arm vs. 7.3 months in the placebo arm; HR, 0.79; P = .007).

The PFS result in the RTOG 0825 trial did not meet the prespecified significance level (P = .004).

AVAglio (NCT00943826): Patients were randomly assigned to receive standard therapy (chemoradiation therapy with temozolomide) or standard therapy plus bevacizumab. OS and PFS were coprimary end points.[18][Level of evidence A1]

Sources: AVAglio · 18 · Level of evidence A1

AVAglio (NCT00943826): Patients were randomly assigned to receive standard therapy (chemoradiation therapy with temozolomide) or standard therapy plus bevacizumab. OS and PFS were coprimary end points.[18][Level of evidence A1]

Bevacizumab did not improve OS (median OS was 16–17 months for each arm). However, it increased median PFS (10.6 months in the bevacizumab arm vs. 6.2 months in the placebo arm; HR, 0.64; P < .0001).

The PFS result was statistically significant and associated with clinical benefit because patients who received bevacizumab remained functionally independent longer (9.0 months in the bevacizumab arm vs. 6.0 months in the standard therapy arm) and had a longer time until their Karnofsky Performance status deteriorated (HR, 0.65; P < .0001).

Patients who received bevacizumab also had delayed initiation of corticosteroids (12.3 months vs. 3.7 months; HR, 0.71; P = .002), and more patients were able to discontinue corticosteroids if they were already taking them (66% in the bevacizumab arm vs. 47% in the standard therapy arm).

The two trials had contradictory results in health-related quality of life (HRQOL) and neurocognitive outcomes studies. In the mandatory HRQOL studies in the AVAglio trial, bevacizumab-treated patients experienced improved HRQOL, but bevacizumab-treated patients in the elective RTOG 0825 studies showed more decline in patient-reported HRQOL and neurocognitive function. The reasons for these discrepancies are unclear.

Based on these results, there is no definite evidence that the addition of bevacizumab to standard therapy is beneficial for all newly diagnosed glioblastoma patients. Certain subgroups may benefit from the addition of bevacizumab, but this is not yet known.

Patients with glioblastoma are appropriate candidates for clinical trials designed to improve local control by adding newer forms of treatment to standard treatment. Information about ongoing clinical trials is available from the NCI website.

Sources: NCI website

Health professional · Treatment of Primary CNS Tumors by Tumor Type

Oligodendroglial Tumors Treatment

Source: Central Nervous System Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: March 28, 2025. Captured 2026-09-09.

Health professional · Treatment of Primary CNS Tumors by Tumor Type / Oligodendroglial Tumors Treatment

Oligodendrogliomas treatment

Source: Central Nervous System Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: March 28, 2025. Captured 2026-09-09.

Patients who have oligodendrogliomas (WHO grade II) generally have better prognoses than do patients who have diffuse astrocytomas. In particular, patients who have oligodendrogliomas with 1p/19q codeletion have a much longer survival.[3] Most of the oligodendrogliomas eventually progress.

Sources: 3

Treatment options for oligodendrogliomas include:

Surgery with or without radiation therapy.

Surgery with radiation therapy and chemotherapy.

Controversy exists concerning the timing of radiation therapy after surgery. A study (EORTC-22845) of 300 patients with low-grade gliomas who had surgery and were randomly assigned to either radiation therapy or watchful waiting, did not show a difference in OS between the two groups.[1][Level of evidence A1] For more information, see the Low-grade tumors section.

Sources: 1 · Level of evidence A1 · Low-grade tumors

For low-grade (WHO grade II) tumors that are considered high risk, radiation therapy followed by six cycles of PCV chemotherapy is a recommended option based on the long-term follow-up results of RTOG-9802, a randomized trial for high-risk, low-grade gliomas.[3][Level of evidence A1] Notably, RTOG-9802 enrolled patients with a variety of tumors, including astrocytomas, oligodendrogliomas, and mixed oligoastrocytomas. In a retrospective subset analysis, only the oligodendroglial tumors appeared to benefit from the addition of PCV.[4] For more information, see the Diffuse astrocytomas treatment section.

Sources: 3 · Level of evidence A1 · 4 · Diffuse astrocytomas treatment

The discovery of the IDH1 and IDH2 variants, which are independent prognostic factors for significantly improved survival in diffuse gliomas, has greatly helped to identify patients with high-risk disease. For more information, see the Diffuse astrocytomas treatment section. In addition, a high proportion of WHO grade II oligodendrogliomas have 1p/19q codeletion, which is a powerful prognostic factor for improved survival.[19-21] Therefore, the presence of IDH1 and IDH2 variants and 1p/19q codeletion should be included in the assessment of high risk. Molecular correlative data from the RTOG-9802 trial, which would be informative about which patients benefited most from the addition of PCV, have not been reported.

Sources: Diffuse astrocytomas treatment · 19 · 21

Health professional · Treatment of Primary CNS Tumors by Tumor Type / Oligodendroglial Tumors Treatment

Anaplastic oligodendrogliomas treatment

Source: Central Nervous System Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: March 28, 2025. Captured 2026-09-09.

Patients with anaplastic oligodendrogliomas (WHO grade III) have a low cure rate with standard local treatment, but their prognoses are generally better than those of patients with anaplastic astrocytomas. Prognoses are particularly better for patients with 1p/19q codeletion, which occurs in most of these tumors. Two phase III randomized trials restricted to patients with anaplastic gliomas (NCT00626990 and NCT00887146) are active. However, efficacy data are not yet available. For more information, see the Anaplastic astrocytomas treatment section. These patients are appropriate candidates for clinical trials designed to improve local control by adding newer forms of treatment.

Sources: NCT00626990 · NCT00887146 · Anaplastic astrocytomas treatment

Information about ongoing clinical trials is available from the NCI website.

Sources: NCI website

Treatment options for anaplastic oligodendrogliomas include:

Surgery plus radiation therapy with or without chemotherapy.[22]

Sources: 22

Evidence (surgery followed by radiation therapy with or without chemotherapy):

Mature results from the EORTC Brain Tumor Group Study 26951 (NCT00002840), a phase III randomized study with 11.7 years of follow-up, demonstrated increased OS and PFS in patients with anaplastic oligodendroglial tumors with six cycles of adjuvant PCV chemotherapy after radiation therapy, compared with radiation therapy alone.[23][Level of evidence A1]

Sources: Brain Tumor Group Study 26951 · 23 · Level of evidence A1

Mature results from the EORTC Brain Tumor Group Study 26951 (NCT00002840), a phase III randomized study with 11.7 years of follow-up, demonstrated increased OS and PFS in patients with anaplastic oligodendroglial tumors with six cycles of adjuvant PCV chemotherapy after radiation therapy, compared with radiation therapy alone.[23][Level of evidence A1]

OS was significantly longer in the radiation therapy and PCV arm (42.3 months vs. 30.6 months; HR, 0.75; 95% CI, 0.60–0.95).

Patients with 1p/19q-codeleted tumors derived more benefit from adjuvant PCV chemotherapy than did those with non–1p/19q-deleted tumors.[23]

Sources: 23

In contrast, the RTOG trial (RTOG-9402 [NCT00002569]) demonstrated no differences in median survival by treatment arm between an 8-week, intensive PCV chemotherapy regimen followed by immediate involved-field-plus-radiation therapy and radiation therapy alone.[24]

Sources: RTOG-9402 · 24

In contrast, the RTOG trial (RTOG-9402 [NCT00002569]) demonstrated no differences in median survival by treatment arm between an 8-week, intensive PCV chemotherapy regimen followed by immediate involved-field-plus-radiation therapy and radiation therapy alone.[24]

In an unplanned subgroup analysis, patients with 1p/19q-codeleted anaplastic oligodendrogliomas and mixed anaplastic astrocytomas demonstrated a median survival of 14.7 years versus 7.3 years (HR, 0.59; 95% CI, 0.37–0.95; P = .03).

For patients with non-codeleted tumors, there was no difference in median survival by treatment arm (2.6 vs. 2.7 years; HR, 0.85; 95% CI, 0.58–1.23; P = .39).[24][Level of evidence A1]

Sources: 24 · Level of evidence A1

Postoperative radiation therapy alone has been compared with postoperative chemotherapy alone in patients with anaplastic gliomas (including 144 astrocytomas, 91 oligoastrocytomas, and 39 oligodendrogliomas) with crossover to the other modality at the time of tumor progression. Of the 139 patients randomly assigned to undergo radiation therapy, 135 were randomly assigned to receive chemotherapy, with a 32-week course of either PCV or single-agent temozolomide (2:1:1 randomization).[12][Levels of evidence A1 and B1]

Sources: 12 · A1 · B1

Postoperative radiation therapy alone has been compared with postoperative chemotherapy alone in patients with anaplastic gliomas (including 144 astrocytomas, 91 oligoastrocytomas, and 39 oligodendrogliomas) with crossover to the other modality at the time of tumor progression. Of the 139 patients randomly assigned to undergo radiation therapy, 135 were randomly assigned to receive chemotherapy, with a 32-week course of either PCV or single-agent temozolomide (2:1:1 randomization).[12][Levels of evidence A1 and B1]

TTF or OS did not differ across the treatment arms and were not affected by the order of the modalities.

Based on these data, CODEL (NCT00887146), a study that randomly assigned patients to receive radiation therapy alone (control arm), radiation therapy with temozolomide, and temozolomide alone (exploratory arm), was halted because radiation therapy alone was no longer considered adequate treatment in patients with anaplastic oligodendroglioma with 1p/19q-codeletions.[25] Temozolomide and PCV chemotherapy in anaplastic oligodendroglioma have not been compared, although in the setting of grade III anaplastic gliomas, no survival difference was seen between PCV chemotherapy and temozolomide.[12,26]

Sources: CODEL · 25 · 12 · 26

The combination of radiation and chemotherapy is not known to be superior in outcome to sequential modality therapy.

A high proportion of anaplastic oligodendrogliomas have IDH1 andIDH2 variants and 1p/19q codeletion, both powerful prognostic factors for improved survival. For more information, see the Diffuse astrocytomas treatment section.[23,24] In addition, PCV chemotherapy has been shown to be predictive in a retrospective analysis of the phase III trials described earlier. Therefore, assessment of these molecular markers may aid management decisions for anaplastic oligodendrogliomas.

Sources: Diffuse astrocytomas treatment · 23 · 24

Health professional · Treatment of Primary CNS Tumors by Tumor Type

Mixed Gliomas Treatment

Source: Central Nervous System Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: March 28, 2025. Captured 2026-09-09.

Patients with mixed glial tumors, which include oligoastrocytoma (WHO grade II) and anaplastic oligoastrocytoma (WHO grade III), have highly variable prognoses based on their status of the IDH1 and IDH2 genes and 1p/19q chromosomes.[27-29] Therefore, the optimal treatment for these tumors as a group is uncertain. Often, they are treated similarly to astrocytic tumors because a subset of tumors may have outcomes similar to WHO grade III astrocytic or WHO grade IV glioblastoma tumors. Testing for these known, strong prognostic molecular markers should be performed, which may help to guide the assessment of risk and subsequent management.

Sources: 27 · 29

Treatment options for mixed gliomas include:

Surgery plus radiation therapy with or without chemotherapy.

For more information, see the Astrocytic Tumors Treatment section.

Sources: Astrocytic Tumors Treatment

Health professional · Treatment of Primary CNS Tumors by Tumor Type

Ependymal Tumors Treatment

Source: Central Nervous System Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: March 28, 2025. Captured 2026-09-09.

Ependymal tumors (WHO grade I) and ependymomas (WHO grade II)—i.e., subependymomas and myxopapillary ependymomas—are often curable.

Treatment options for grades I and II ependymal tumors include:

Surgery alone if the tumor is totally resectable.

Surgery followed by radiation therapy to known or suspected residual tumor.

Patients with anaplastic ependymomas (WHO grade III) have variable prognoses that depend on the location and extent of disease. Frequently, but not invariably, patients with anaplastic ependymomas have worse prognoses than do those patients with lower-grade ependymal tumors.

Treatment options for anaplastic ependymomas include:

Surgery plus radiation therapy.[30]

Sources: 30

Health professional · Treatment of Primary CNS Tumors by Tumor Type

Embryonal Cell Tumors (Medulloblastomas) Treatment

Source: Central Nervous System Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: March 28, 2025. Captured 2026-09-09.

Medulloblastoma occurs primarily in children but may also occur in adults.[31] For more information, see Childhood Medulloblastoma and Other Central Nervous System Embryonal Tumors Treatment.

Sources: 31 · Childhood Medulloblastoma and Other Central Nervous System Embryonal Tumors Treatment

Treatment options for medulloblastomas include:

Surgery plus craniospinal radiation therapy for patients with good-risk disease.[32]

Sources: 32

Surgery plus craniospinal radiation therapy and various chemotherapy regimens for patients with poor-risk disease (under clinical evaluation).[32]

Sources: 32

Health professional · Treatment of Primary CNS Tumors by Tumor Type

Pineal Parenchymal Tumors Treatment

Source: Central Nervous System Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: March 28, 2025. Captured 2026-09-09.

Pineocytomas (WHO grade II), pineoblastomas (WHO grade IV), and pineal parenchymal tumors of intermediate differentiation are diverse tumors that require special consideration. Pineocytomas are slow-growing tumors and prognosis varies.

Pineoblastomas grow more rapidly and patients with these tumors have worse prognoses. Pineal parenchymal tumors of intermediate differentiation have unpredictable growth and clinical behavior.

Treatment options for pineal parenchymal tumors include:

Surgery plus radiation therapy for pineocytoma.

Surgery plus radiation therapy and chemotherapy for pineoblastoma.

Health professional · Treatment of Primary CNS Tumors by Tumor Type

Meningeal Tumors Treatment

Source: Central Nervous System Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: March 28, 2025. Captured 2026-09-09.

WHO grade I meningiomas are usually curable when they are resectable. With the increasing use of sensitive neuroimaging tools, there has been more detection of asymptomatic low-grade meningiomas. Most appear to show minimal growth and can often be safely observed while therapy is deferred until growth or the development of symptoms.[33,34]

Sources: 33 · 34

Treatment options for meningeal tumors include:

Active surveillance with deferred treatment, especially for incidentally discovered asymptomatic tumors.[33,34]

Sources: 33 · 34

Surgery.

Stereotactic radiosurgery for tumors smaller than 3 cm.

Surgery plus radiation therapy in selected cases, such as for patients with known or suspected residual disease or with recurrence after previous surgery.

Fractionated radiation therapy for patients with unresectable tumors.[35]

Sources: 35

The prognoses for patients with WHO grade II meningiomas (atypical, clear cell, and chordoid), WHO grade III meningiomas (anaplastic/malignant, rhabdoid, and papillary), and hemangiopericytomas are worse than the prognoses for patients with low-grade meningiomas because complete resections are less commonly feasible, and the proliferative capacity is greater.

Treatment options for grades II and III meningiomas and hemangiopericytomas include:

Surgery plus radiation therapy.

Health professional · Treatment of Primary CNS Tumors by Tumor Type

Germ Cell Tumors Treatment

Source: Central Nervous System Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: March 28, 2025. Captured 2026-09-09.

The prognoses and treatment of patients with germ cell tumors—which include germinomas, embryonal carcinomas, choriocarcinomas, and teratomas—depend on tumor histology, tumor location, presence and levels of biological markers, and surgical resectability.

Health professional · Treatment of Primary CNS Tumors by Tumor Type

Treatment of Tumors of the Sellar Region

Source: Central Nervous System Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: March 28, 2025. Captured 2026-09-09.

Craniopharyngiomas (WHO grade I) are often curable.

Treatment options for craniopharyngiomas include:

Surgery alone if the tumor is totally resectable.

Debulking surgery plus radiation therapy if the tumor is unresectable.

Health professional · Treatment of Primary CNS Tumors by Tumor Type

Treatment Options Under Clinical Evaluation for Primary CNS Tumors

Source: Central Nervous System Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: March 28, 2025. Captured 2026-09-09.

Patients who have central nervous system (CNS) tumors that are either infrequently curable or unresectable should consider enrollment in clinical trials. Information about ongoing clinical trials is available from the NCI website.

Sources: NCI website

Heavy-particle radiation, such as proton-beam therapy, carries the theoretical advantage of delivering high doses of ionizing radiation to the tumor bed while sparing surrounding brain tissue. The data are preliminary for this investigational technique and are not widely available.

Novel biological therapies under clinical evaluation for patients with CNS tumors include:[36]

Sources: 36

Dendritic cell vaccination.[37]

Sources: 37

Tyrosine kinase receptor inhibitors.[38]

Sources: 38

Farnesyl transferase inhibitors.

Viral-based gene therapy.[39,40]

Sources: 39 · 40

Oncolytic viruses.

Epidermal growth factor-receptor inhibitors.

Vascular endothelial growth factor inhibitors.[36]

Sources: 36

Other antiangiogenesis agents.

Health professional

Treatment of Primary Tumors of the Spinal Axis

Source: Central Nervous System Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: March 28, 2025. Captured 2026-09-09.

Surgery and radiation therapy are the primary modalities used to treat tumors of the spinal axis. Therapeutic options vary according to the histology of the tumor.[1] The experience with chemotherapy for primary spinal cord tumors is limited. No reports of controlled clinical trials are available for these types of tumors.[1,2] Chemotherapy is indicated for most patients with leptomeningeal involvement from a primary or metastatic tumor and positive cerebrospinal fluid cytology.[1] Most patients require treatment with corticosteroids, particularly if they are receiving radiation therapy.

Sources: 1 · 1 · 2 · 1

Patients who have spinal axis tumors that are either infrequently curable or unresectable should consider enrollment in clinical trials. Information about ongoing clinical trials is available from the NCI website.

Sources: NCI website

Health professional · Metastatic Brain Tumors

Treatment of Metastatic Brain Tumors

Source: Central Nervous System Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: March 28, 2025. Captured 2026-09-09.

The optimal therapy for patients with brain metastases continues to evolve.[1,2,5] The following treatments have been used in the management of metastatic brain tumors:

Sources: 1 · 2 · 5

Radiation therapy.

Radiosurgery.

Surgical resection.

Corticosteroids.

Anticonvulsants.

Because most cases of brain metastases involve multiple metastases, a mainstay of therapy has historically been whole-brain radiation therapy (WBRT). However, stereotactic radiosurgery has become increasingly common. The role of radiosurgery continues to be defined. Stereotactic radiosurgery in combination with WBRT has been assessed.

Surgery is indicated to obtain tissue from a metastasis with an unknown primary tumor or to decompress a symptomatic dominant lesion that is causing significant mass effect.

Chemotherapy is usually not the primary therapy for most patients; however, it may have a role in the treatment of patients with brain metastases from chemosensitive tumors and can even be curative when combined with radiation for metastatic testicular germ cell tumors.[1,6] Intrathecal chemotherapy is also used for meningeal spread of metastatic tumors.

Sources: 1 · 6

Health professional · Metastatic Brain Tumors / Treatment of Metastatic Brain Tumors

Treatment for patients with one to four metastases

Source: Central Nervous System Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: March 28, 2025. Captured 2026-09-09.

Health professional · Metastatic Brain Tumors / Treatment of Metastatic Brain Tumors / Treatment for patients with one to four metastases

Treatment options for patients with one to four metastases

Source: Central Nervous System Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: March 28, 2025. Captured 2026-09-09.

About 10% to 15% of patients with cancer will have a single brain metastasis. Radiation therapy is the mainstay of palliation for these patients. The extent of extracranial disease can influence treatment of the brain lesions. In the presence of extensive active systemic disease, surgery provides little benefit for overall survival (OS). In patients with stable minimal extracranial disease, combined-modality treatment may be considered, using surgical resection followed by radiation therapy. However, the published literature does not provide clear guidance.

Treatment options for patients with one to four metastases include:

WBRT with or without surgical resection.

WBRT with or without stereotactic radiosurgery.

Focal therapy alone (surgical resection or stereotactic radiosurgery).

Evidence (treatment for one to four metastases):

Three randomized trials examined resection of solitary brain metastases followed by WBRT versus WBRT alone, totaling 195 randomly assigned patients.[7-9] The process that necessarily goes into selecting appropriate patients for surgical resection may account for the small numbers in each trial. In the first trial,[7][Level of evidence B1] performed at a single center, all patients were selected and operated upon by one surgeon.

Sources: 7 · 9 · 7 · Level of evidence B1

Three randomized trials examined resection of solitary brain metastases followed by WBRT versus WBRT alone, totaling 195 randomly assigned patients.[7-9] The process that necessarily goes into selecting appropriate patients for surgical resection may account for the small numbers in each trial. In the first trial,[7][Level of evidence B1] performed at a single center, all patients were selected and operated upon by one surgeon.

The first two trials showed an improvement in survival in the surgery group,[7,8] but the third trial showed a trend in favor of the WBRT-only group.[9]

Sources: 7 · 8 · 9

The three trials were combined in a trial-level meta-analysis.[10]

Sources: 10

Three randomized trials examined resection of solitary brain metastases followed by WBRT versus WBRT alone, totaling 195 randomly assigned patients.[7-9] The process that necessarily goes into selecting appropriate patients for surgical resection may account for the small numbers in each trial. In the first trial,[7][Level of evidence B1] performed at a single center, all patients were selected and operated upon by one surgeon. › The three trials were combined in a trial-level meta-analysis.[10]

The combined analysis did not show a statistically significant difference in OS (hazard ratio [HR], 0.72; 95% confidence interval [CI], 0.34–1.53; P = .4); or in death from neurological causes (relative riskdeath, 0.68; 95% CI, 0.43–1.09; P = .11).[10]

Sources: 10

One of the trials reported that combined therapy increased the duration of functionally independent survival.[7][Level of evidence B1]

Sources: 7 · Level of evidence B1

None of the trials assessed or reported quality of life.

The need for WBRT after resection of solitary brain metastases has been studied.[11] Patients were randomly assigned to either undergo postoperative WBRT or receive no further treatment after resection.

Sources: 11

The need for WBRT after resection of solitary brain metastases has been studied.[11] Patients were randomly assigned to either undergo postoperative WBRT or receive no further treatment after resection.

Patients in the WBRT group were less likely to have tumor progression in the brain and were significantly less likely to die of neurological causes.

OS was the same in each group, and there was no difference in duration of functional independence.

One additional randomized study of observation versus WBRT after either surgery or stereotactic radiosurgery for solitary brain metastases was closed after 19 patients had been entered because of slow accrual; therefore, little can be deduced from the trial.[12]

Sources: 12

A Radiation Therapy Oncology Group (RTOG) study (RTOG-9508) randomly assigned 333 patients with one to three metastases with a maximum diameter of 4 cm to WBRT (37.5 Gy over 3 weeks) with or without a stereotactic boost.[13] Patients with active systemic disease requiring therapy were excluded. The primary end point was OS with predefined hypotheses in both the full study population and the 186 patients with a solitary metastasis (and no statistical adjustment of P values for the two separate hypotheses).[13][Levels of evidence B1 for the full study population and A1 for patients with solitary metastases]

Sources: RTOG-9508 · 13 · 13 · B1 · A1

A Radiation Therapy Oncology Group (RTOG) study (RTOG-9508) randomly assigned 333 patients with one to three metastases with a maximum diameter of 4 cm to WBRT (37.5 Gy over 3 weeks) with or without a stereotactic boost.[13] Patients with active systemic disease requiring therapy were excluded. The primary end point was OS with predefined hypotheses in both the full study population and the 186 patients with a solitary metastasis (and no statistical adjustment of P values for the two separate hypotheses).[13][Levels of evidence B1 for the full study population and A1 for patients with solitary metastases]

Mean OS in the combined-therapy group was 5.7 months, and mean OS in the WBRT-alone group was 6.5 months (P = .14).

A Radiation Therapy Oncology Group (RTOG) study (RTOG-9508) randomly assigned 333 patients with one to three metastases with a maximum diameter of 4 cm to WBRT (37.5 Gy over 3 weeks) with or without a stereotactic boost.[13] Patients with active systemic disease requiring therapy were excluded. The primary end point was OS with predefined hypotheses in both the full study population and the 186 patients with a solitary metastasis (and no statistical adjustment of P values for the two separate hypotheses).[13][Levels of evidence B1 for the full study population and A1 for patients with solitary metastases] › Mean OS in the combined-therapy group was 5.7 months, and mean OS in the WBRT-alone group was 6.5 months (P = .14).

In the subgroup with solitary metastases, OS was better in the combined-therapy group (6.5 months vs. 4.9 months; P = .039 in univariate analysis; P = .053 in a multivariable analysis adjusting for baseline prognostic factors).

In patients with multiple metastases, survival was 5.8 months in the combined-therapy group versus 6.7 months in the WBRT-only group (P = .98).

The combined-treatment group had a survival advantage of 2.5 months in patients with a single metastasis but not in patients with multiple lesions.

A Radiation Therapy Oncology Group (RTOG) study (RTOG-9508) randomly assigned 333 patients with one to three metastases with a maximum diameter of 4 cm to WBRT (37.5 Gy over 3 weeks) with or without a stereotactic boost.[13] Patients with active systemic disease requiring therapy were excluded. The primary end point was OS with predefined hypotheses in both the full study population and the 186 patients with a solitary metastasis (and no statistical adjustment of P values for the two separate hypotheses).[13][Levels of evidence B1 for the full study population and A1 for patients with solitary metastases]

Local control was better in the full population with combined therapy.

At the 6-month follow-up, Karnofsky Performance status (considered a soft end point because of its imprecision and subjectivity) was better in the combined-therapy group, but there was no difference in mental status between the treatment groups. Acute and late toxicities were similar in both treatment arms. Quality of life was not assessed.

A phase III randomized trial compared adjuvant WBRT with observation after surgery or radiosurgery for a limited number of brain metastases in patients with stable solid tumors.[14][Level of evidence A3]

Sources: 14 · Level of evidence A3

A phase III randomized trial compared adjuvant WBRT with observation after surgery or radiosurgery for a limited number of brain metastases in patients with stable solid tumors.[14][Level of evidence A3]

Health-related quality of life was improved in the observation-only arm, compared with WBRT.

Patients in the observation arm had better mean scores in physical, role, and cognitive functioning at 9 months.

In an exploratory analysis, statistically significant worse scores for bladder control, communication deficit, drowsiness, hair loss, motor dysfunction, leg weakness, appetite loss, constipation, nausea/vomiting, pain, and social functioning were observed in patients who underwent WBRT, compared with those who underwent observation only.

A meta-analysis of two trials with a total of 358 participants found no statistically significant difference in OS between the WBRT plus stereotactic radiosurgery group and the WBRT-alone group (HR, 0.82; 95% CI, 0.65–1.02).[15][Level of evidence B1]

Sources: 15 · Level of evidence B1

A meta-analysis of two trials with a total of 358 participants found no statistically significant difference in OS between the WBRT plus stereotactic radiosurgery group and the WBRT-alone group (HR, 0.82; 95% CI, 0.65–1.02).[15][Level of evidence B1]

Patients in the WBRT plus stereotactic radiosurgery group had decreased local failure, compared with patients who received WBRT alone (HR, 0.27; 95% CI, 0.14–0.52).

Unchanged or improved Karnofsky Performance status at 6 months was seen in 43% of patients in the combined-therapy group versus 28% in the WBRT-alone group (P = .03).

A study that had a primary end point of learning and neurocognition, using a standardized test for total recall, was stopped by the Data and Safety Monitoring Board because of worse outcomes in the WBRT group.[16][Level of evidence B1]

Sources: 16 · Level of evidence B1

Given this body of information, focal therapy plus WBRT or focal therapy alone, with close follow-up with serial MRIs and initiation of salvage therapy when clinically indicated, appear to be reasonable treatment options. The pros and cons of each approach should be discussed with the patient.

Several randomized trials have been performed that were designed with varying primary end points to address whether WBRT is necessary after focal treatment. The results can be summarized as follows:[16-18]

Sources: 16 · 18

Studies consistently show that the addition of WBRT to focal therapy decreases the risk of progression and new metastases in the brain.

The addition of WBRT does not improve OS.

The decrease in risk of intracranial disease progression does not translate into improved functional or neurological status, nor does it appear to decrease the risk of death from neurological deterioration.

About one-half or more of the patients who receive focal therapy alone ultimately require salvage therapy, such as WBRT or radiosurgery, compared with about one-quarter of the patients who are given up-front WBRT.

The impact of better local control associated with WBRT on quality of life has not been reported and remains an open question.

Health professional

Treatment of Recurrent CNS Tumors

Source: Central Nervous System Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: March 28, 2025. Captured 2026-09-09.

Patients who have recurrent central nervous system (CNS) tumors are rarely curable and should consider enrollment in clinical trials. Information about ongoing clinical trials is available from the NCI website.

Sources: NCI website

Treatment options for recurrent CNS tumors include:

Chemotherapy.

Sources: Chemotherapy

Antiangiogenesis therapy.

Sources: Antiangiogenesis therapy

Radiation therapy.

Sources: Radiation therapy

Surgery.

Sources: Surgery

Health professional · Treatment of Recurrent CNS Tumors

Chemotherapy

Source: Central Nervous System Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: March 28, 2025. Captured 2026-09-09.

Health professional · Treatment of Recurrent CNS Tumors / Chemotherapy

Localized chemotherapy (carmustine wafer)

Source: Central Nervous System Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: March 28, 2025. Captured 2026-09-09.

Carmustine wafers have been investigated for the treatment of recurrent malignant gliomas, but the impact on survival is less clear than at the time of initial diagnosis and resection.

Evidence (localized chemotherapy):

In a multicenter, randomized, placebo-controlled trial, 222 patients with recurrent malignant primary brain tumors requiring reoperation were randomly assigned to receive implanted carmustine wafers or placebo biodegradable wafers.[1][Level of evidence A1] Approximately one-half of the patients had received previous systemic chemotherapy. The two treatment groups were well balanced at baseline.

Sources: 1 · Level of evidence A1

In a multicenter, randomized, placebo-controlled trial, 222 patients with recurrent malignant primary brain tumors requiring reoperation were randomly assigned to receive implanted carmustine wafers or placebo biodegradable wafers.[1][Level of evidence A1] Approximately one-half of the patients had received previous systemic chemotherapy. The two treatment groups were well balanced at baseline.

Median survival was 31 weeks in the group receiving carmustine wafers versus 23 weeks in the group receiving placebo wafers. The statistical significance between the two overall survival curves depended on the method of analysis.

The hazard ratio (HR) for risk of dying in the direct intention-to-treat comparison between the two groups was 0.83 (95% confidence interval [CI], 0.63–1.10; P = .19). The baseline characteristics were similar in the two groups, but the investigators performed an additional analysis, adjusting for prognostic factors, because they felt that even small differences in baseline characteristics could have a powerful influence on outcomes. In the adjusted proportional hazards model, the HR for risk of death was 0.67 (95% CI, 0.51–0.90; P = .006). The investigators emphasized this latter analysis and reported this as a positive trial.[1][Level of evidence A1]

Sources: 1 · Level of evidence A1

A Cochrane Collaboration systematic review of chemotherapeutic wafers for high-grade glioma focused on the unadjusted analysis and reported the same trial as negative.[2]

Sources: 2

Health professional · Treatment of Recurrent CNS Tumors / Chemotherapy

Systemic chemotherapy

Source: Central Nervous System Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: March 28, 2025. Captured 2026-09-09.

Systemic therapy (e.g., temozolomide, lomustine, or the combination of procarbazine, a nitrosourea, and vincristine [PCV] in patients who have not previously received the drugs) has been used at the time of recurrence of primary malignant brain tumors. However, this approach has not been tested in controlled studies. Patient-selection factors likely play a strong role in determining outcomes, so the impact of therapy on survival is not clear.

Health professional · Treatment of Recurrent CNS Tumors

Antiangiogenesis Therapy

Source: Central Nervous System Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: March 28, 2025. Captured 2026-09-09.

In 2009, the U.S. Food and Drug Administration (FDA) granted accelerated approval of bevacizumab monotherapy for patients with progressive glioblastoma. The indication was granted under the FDA’s accelerated approval program that permits the use of certain surrogate end points or an effect on a clinical end point other than survival or irreversible morbidity as bases for approvals of products intended for serious or life-threatening illnesses or conditions.

The approval was based on the demonstration of improved objective response rates observed in two historically controlled, single-arm, or noncomparative phase II trials.[3,4][Level of evidence C3] Based on these data and the FDA approval, bevacizumab monotherapy has become standard therapy for recurrent glioblastoma.

Sources: 3 · 4 · Level of evidence C3

Evidence (antiangiogenesis therapy):

The FDA independently reviewed an open-label, multicenter, noncomparative phase II study that randomly assigned 167 patients with recurrent glioblastoma multiforme (GBM) to receive bevacizumab alone or bevacizumab in combination with irinotecan.[3] However, only efficacy data from the bevacizumab monotherapy arm (n = 85) were used to support drug approval.

Sources: 3

The FDA independently reviewed an open-label, multicenter, noncomparative phase II study that randomly assigned 167 patients with recurrent glioblastoma multiforme (GBM) to receive bevacizumab alone or bevacizumab in combination with irinotecan.[3] However, only efficacy data from the bevacizumab monotherapy arm (n = 85) were used to support drug approval.

Tumor responses were observed in 26% of patients treated with bevacizumab alone, and the median duration of response in these patients was 4.2 months.

Based on this externally controlled trial, the incidence of adverse events associated with bevacizumab did not appear to be significantly increased in GBM patients.

The FDA independently assessed another single-arm, single-institution trial in which 56 patients with recurrent glioblastoma were treated with bevacizumab alone.[4]

Sources: 4

The FDA independently assessed another single-arm, single-institution trial in which 56 patients with recurrent glioblastoma were treated with bevacizumab alone.[4]

Responses were observed in 20% of patients, and the median duration of response was 3.9 months.

No data are available from prospective randomized controlled trials demonstrating improvement in health outcomes, such as disease-related symptoms or increased survival with the use of bevacizumab to treat glioblastoma.

Health professional · Treatment of Recurrent CNS Tumors

Radiation Therapy

Source: Central Nervous System Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: March 28, 2025. Captured 2026-09-09.

Because there are no randomized trials, the role of repeat radiation after disease progression or the development of radiation-induced cancers is also ill defined. Interpretation is difficult because the literature is limited to small retrospective case series.[5] The decision must be made carefully because of the risk of neurocognitive deficits and radiation necrosis.

Sources: 5

Health professional · Treatment of Recurrent CNS Tumors

Surgery

Source: Central Nervous System Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: March 28, 2025. Captured 2026-09-09.

Re-resection of recurrent CNS tumors is an option for some patients. However, most patients do not qualify because of a deteriorating condition or technically inoperable tumors. The evidence is limited to noncontrolled studies and case series of patients who are healthy enough and have tumors that are small enough to technically debulk. The impact on survival of reoperation versus patient selection is not known.

For patients · General Information About Adult Central Nervous System Tumors

Certain factors affect prognosis (chance of recovery) and treatment options.

Source: Adult Central Nervous System Tumors Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: January 5, 2024. Captured 2026-09-09.

The prognosis and treatment options for primary brain and spinal cord tumors depend on the following:

The type and grade of the tumor.

Where the tumor is in the brain or spinal cord.

Whether the tumor can be removed by surgery.

Whether cancer cells remain after surgery.

Whether there are certain changes in the chromosomes.

Whether the cancer has just been diagnosed or has recurred (come back).

The patient's general health.

The prognosis and treatment options for metastatic brain and spinal cord tumors depend on the following:

Whether there are more than two tumors in the brain or spinal cord.

Where the tumor is in the brain or spinal cord.

How well the tumor responds to treatment.

Whether the primary tumor continues to grow or spread.

For patients · Stages of Adult Central Nervous System Tumors

Imaging tests may be repeated after surgery to help plan more treatment.

Source: Adult Central Nervous System Tumors Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: January 5, 2024. Captured 2026-09-09.

Some of the tests and procedures used to diagnose a brain or spinal cord tumor may be repeated after treatment to find out how much tumor is left.

Sources: tests and procedures · diagnose

For patients · Stages of Adult Central Nervous System Tumors

Central nervous system (CNS) tumors often recur, sometimes many years after treatment.

Source: Adult Central Nervous System Tumors Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: January 5, 2024. Captured 2026-09-09.

A recurrent CNS tumor is a tumor that has recurred (come back) after it has been treated. The tumor may recur at the same place as the first tumor or in other parts of the CNS.

Sources: CNS

For patients

Treatment Option Overview

Source: Adult Central Nervous System Tumors Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: January 5, 2024. Captured 2026-09-09.

For patients · Treatment Option Overview

Key Points

Source: Adult Central Nervous System Tumors Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: January 5, 2024. Captured 2026-09-09.

There are different types of treatment for patients with adult brain and spinal cord tumors.

The following types of treatment are used:

The following types of treatment are used:

Active surveillance

Surgery

Radiation therapy

Chemotherapy

Targeted therapy

Supportive care is given to lessen the problems caused by the disease or its treatment.

New types of treatment are being tested in clinical trials.

New types of treatment are being tested in clinical trials.

Proton beam radiation therapy

Immunotherapy

Treatment for adult central nervous system tumors may cause side effects.

Patients may want to think about taking part in a clinical trial.

Patients can enter clinical trials before, during, or after starting their cancer treatment.

Follow-up tests may be needed.

For patients · Treatment Option Overview

There are different types of treatment for patients with adult brain and spinal cord tumors.

Source: Adult Central Nervous System Tumors Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: January 5, 2024. Captured 2026-09-09.

Different types of treatment are available for patients with adult brain and spinal cord tumors. Some treatments are standard (the currently used treatment), and some are being tested in clinical trials. A treatment clinical trial is a research study meant to help improve current treatments or obtain information on new treatments for patients with cancer. When clinical trials show that a new treatment is better than the standard treatment, the new treatment may become the standard treatment. Patients may want to think about taking part in a clinical trial. Some clinical trials are open only to patients who have not started treatment.

Sources: brain · spinal cord · standard · clinical trials · research study

For patients · Treatment Option Overview

The following types of treatment are used:

Source: Adult Central Nervous System Tumors Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: January 5, 2024. Captured 2026-09-09.

For patients · Treatment Option Overview / The following types of treatment are used:

Active surveillance

Source: Adult Central Nervous System Tumors Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: January 5, 2024. Captured 2026-09-09.

Active surveillance is closely watching a patient’s condition but not giving any treatment unless there are changes in test results that show the condition is getting worse. Active surveillance may be used to avoid or delay the need for treatments such as radiation therapy or surgery, which can cause side effects or other problems. During active surveillance, certain exams and tests are done on a regular schedule. Active surveillance may be used for very slow-growing tumors that do not cause symptoms.

Sources: Active surveillance · radiation therapy · side effects · symptoms

For patients · Treatment Option Overview / The following types of treatment are used:

Surgery

Source: Adult Central Nervous System Tumors Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: January 5, 2024. Captured 2026-09-09.

Surgery may be used to diagnose and treat adult brain and spinal cord tumors. Removing tumor tissue helps decrease pressure of the tumor on nearby parts of the brain. See the General Information section of this summary.

Sources: General Information

After the doctor removes all the cancer that can be seen at the time of the surgery, some patients may be given chemotherapy or radiation therapy after surgery to kill any cancer cells that are left. Treatment given after the surgery, to lower the risk that the cancer will come back, is called adjuvant therapy.

Sources: chemotherapy · adjuvant therapy

For patients · Treatment Option Overview / The following types of treatment are used:

Radiation therapy

Source: Adult Central Nervous System Tumors Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: January 5, 2024. Captured 2026-09-09.

Radiation therapy is a cancer treatment that uses high-energy x-rays or other types of radiation to kill cancer cells or keep them from growing. External radiation therapy uses a machine outside the body to send radiation toward the area of the body with cancer.

Sources: x-rays · radiation · External radiation therapy

Certain ways of giving external radiation therapy can help keep radiation from damaging nearby healthy tissue. These types of radiation therapy include the following:

Conformal radiation therapy: Conformal radiation therapy uses a computer to make a 3-dimensional (3-D) picture of the tumor and shapes the radiation beams to fit the tumor.

Sources: Conformal radiation therapy · 3-dimensional

Intensity-modulated radiation therapy (IMRT): IMRT is a type of 3-dimensional (3-D) radiation therapy that uses a computer to make pictures of the size and shape of the tumor. Thin beams of radiation of different intensities (strengths) are aimed at the tumor from many angles.

Sources: Intensity-modulated radiation therapy

Stereotactic radiosurgery: Stereotactic radiosurgery uses a rigid head frame that is attached to the skull to keep the head still during the radiation treatment. A machine aims a single large dose of radiation directly at the tumor. This procedure does not involve surgery. It is also called stereotaxic radiosurgery, radiosurgery, and radiation surgery.

Sources: Stereotactic radiosurgery · skull · dose

For patients · Treatment Option Overview / The following types of treatment are used:

Chemotherapy

Source: Adult Central Nervous System Tumors Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: January 5, 2024. Captured 2026-09-09.

Chemotherapy is a cancer treatment that uses drugs to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. When chemotherapy is taken by mouth or injected into a vein or muscle, the drugs enter the bloodstream and can reach cancer cells throughout the body (systemic chemotherapy). Although most cannot, some chemotherapy drugs can cross the blood-brain barrier and reach tumor cells in the brain. Chemotherapy that is placed directly into the cerebrospinal fluid is called intrathecal chemotherapy. When chemotherapy is inserted in an organ, such as the brain, or a body cavity, the drugs mainly affect cancer cells in those areas (regional chemotherapy).

Sources: injected · systemic chemotherapy · blood-brain barrier · cerebrospinal fluid · intrathecal chemotherapy · cavity · regional chemotherapy

To treat brain tumors, a wafer that dissolves may be used to deliver a chemotherapy drug directly to the brain tumor site after the tumor has been removed by surgery. The way the chemotherapy is given depends on the type and grade of tumor and where it is in the brain.

Sources: wafer · grade

See Drugs Approved for Brain Tumors for more information.

Sources: Drugs Approved for Brain Tumors

For patients · Treatment Option Overview / The following types of treatment are used:

Targeted therapy

Source: Adult Central Nervous System Tumors Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: January 5, 2024. Captured 2026-09-09.

Targeted therapy is a type of treatment that uses drugs or other substances to identify and attack specific cancer cells.

Sources: Targeted therapy

Monoclonal antibody therapy: Monoclonal antibodies are immune system proteins made in the laboratory to treat many diseases, including cancer. As a cancer treatment, these antibodies can attach to a specific target on cancer cells or other cells that may help cancer cells grow. The antibodies are able to then kill the cancer cells, block their growth, or keep them from spreading. Monoclonal antibodies are given by infusion. They may be used alone or to carry drugs, toxins, or radioactive material directly to cancer cells.Bevacizumab is a monoclonal antibody that binds to a protein called vascular endothelial growth factor (VEGF) and may prevent the growth of new blood vessels that tumors need to grow. Bevacizumab is used in the treatment of recurrent glioblastoma.

Sources: Monoclonal antibody · therapy · immune system · proteins · antibodies · infusion · toxins · radioactive · Bevacizumab · vascular endothelial growth factor · blood vessels · recurrent · glioblastoma

Other types of targeted therapies are being studied for adult brain tumors, including tyrosine kinase inhibitors and new VEGF inhibitors.

Sources: tyrosine kinase inhibitors

See Drugs Approved for Brain Tumors for more information.

Sources: Drugs Approved for Brain Tumors

For patients · Treatment Option Overview

Supportive care is given to lessen the problems caused by the disease or its treatment.

Source: Adult Central Nervous System Tumors Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: January 5, 2024. Captured 2026-09-09.

This therapy controls problems or side effects caused by the disease or its treatment and improves quality of life. For brain tumors, supportive care includes drugs to control seizures and fluid buildup or swelling in the brain.

Sources: side effects · quality of life · seizures

For patients · Treatment Option Overview

New types of treatment are being tested in clinical trials.

Source: Adult Central Nervous System Tumors Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: January 5, 2024. Captured 2026-09-09.

This summary section refers to new treatments being studied in clinical trials, but it may not mention every new treatment being studied. Information about clinical trials is available from the NCI website.

Sources: NCI website

For patients · Treatment Option Overview / New types of treatment are being tested in clinical trials.

Proton beam radiation therapy

Source: Adult Central Nervous System Tumors Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: January 5, 2024. Captured 2026-09-09.

Proton beam radiation therapy is a type of high-energy, external radiation therapy that uses streams of protons (tiny particles with a positive charge) to kill tumor cells. This type of treatment can lower the amount of radiation damage to healthy tissue near a tumor. It is used to treat cancers of the head, neck, and spine and organs such as the brain, eye, lung, and prostate. Proton beam radiation is different from x-ray radiation.

Sources: Proton beam radiation therapy · spine · lung · prostate

For patients · Treatment Option Overview / New types of treatment are being tested in clinical trials.

Immunotherapy

Source: Adult Central Nervous System Tumors Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: January 5, 2024. Captured 2026-09-09.

Immunotherapy is a treatment that uses the patient's immune system to fight cancer. Substances made by the body or made in a laboratory are used to boost, direct, or restore the body's natural defenses against cancer.

Sources: Immunotherapy · immune system

Immunotherapy is being studied for the treatment of some types of brain tumors. Treatments may include the following:

Dendritic cell vaccine therapy.

Sources: Dendritic cell vaccine

Gene therapy.

Sources: Gene therapy

For patients · Treatment Option Overview

Treatment for adult central nervous system tumors may cause side effects.

Source: Adult Central Nervous System Tumors Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: January 5, 2024. Captured 2026-09-09.

For information about side effects caused by treatment for cancer, visit our Side Effects page.

Sources: side effects · Side Effects

For patients · Treatment Option Overview

Patients may want to think about taking part in a clinical trial.

Source: Adult Central Nervous System Tumors Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: January 5, 2024. Captured 2026-09-09.

For some patients, taking part in a clinical trial may be the best treatment choice. Clinical trials are part of the cancer research process. Clinical trials are done to find out if new cancer treatments are safe and effective or better than the standard treatment.

Sources: clinical trial · standard treatment

Many of today's standard treatments for cancer are based on earlier clinical trials. Patients who take part in a clinical trial may receive the standard treatment or be among the first to receive a new treatment.

Patients who take part in clinical trials also help improve the way cancer will be treated in the future. Even when clinical trials do not lead to effective new treatments, they often answer important questions and help move research forward.

For patients · Treatment Option Overview

Patients can enter clinical trials before, during, or after starting their cancer treatment.

Source: Adult Central Nervous System Tumors Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: January 5, 2024. Captured 2026-09-09.

Some clinical trials only include patients who have not yet received treatment. Other trials test treatments for patients whose cancer has not gotten better. There are also clinical trials that test new ways to stop cancer from recurring (coming back) or reduce the side effects of cancer treatment.

Sources: side effects

Clinical trials are taking place in many parts of the country. Information about clinical trials supported by NCI can be found on NCI’s clinical trials search webpage. Clinical trials supported by other organizations can be found on the ClinicalTrials.gov website.

Sources: clinical trials search · ClinicalTrials.gov

For patients · Treatment Option Overview

Follow-up tests may be needed.

Source: Adult Central Nervous System Tumors Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: January 5, 2024. Captured 2026-09-09.

As you go through treatment, you will have follow-up tests or check-ups. Some tests that were done to diagnose or stage the cancer may be repeated to see how well the treatment is working. Decisions about whether to continue, change, or stop treatment may be based on the results of these tests.

Sources: diagnose · stage

Some of the tests will continue to be done from time to time after treatment has ended. The results of these tests can show if your condition has changed or if the cancer has recurred (come back).

The following tests and procedures may be used to check whether a brain tumor has come back after treatment:

SPECT scan (single photon emission computed tomography scan): A procedure to find malignant tumor cells in the brain. A small amount of a radioactive substance is injected into a vein or inhaled through the nose. As the substance travels through the blood, a camera rotates around the head and takes pictures of the brain. A computer uses the pictures to make a 3-dimensional (3-D) image of the brain. There will be increased blood flow and more activity in areas where cancer cells are growing. These areas will show up brighter in the picture.

Sources: SPECT · malignant · inhaled · 3-dimensional

PET scan (positron emission tomography scan): A procedure to find malignant tumor cells in the body. A small amount of radioactive glucose (sugar) is injected into a vein. The PET scanner rotates around the body and makes a picture of where glucose is being used in the brain. Malignant tumor cells show up brighter in the picture because they are more active and take up more glucose than normal cells do.

Sources: PET scan · scanner

For patients

Treatment of Primary Adult Brain Tumor by Type of Tumor

Source: Adult Central Nervous System Tumors Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: January 5, 2024. Captured 2026-09-09.

For information about the treatments listed below, see the Treatment Option Overview section.

Sources: Treatment Option Overview

For patients · Treatment of Primary Adult Brain Tumor by Type of Tumor

Astrocytic Tumors

Source: Adult Central Nervous System Tumors Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: January 5, 2024. Captured 2026-09-09.

For patients · Treatment of Primary Adult Brain Tumor by Type of Tumor / Astrocytic Tumors

Brain Stem Gliomas

Source: Adult Central Nervous System Tumors Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: January 5, 2024. Captured 2026-09-09.

Treatment of brain stem gliomas may include radiation therapy.

Sources: brain stem gliomas · radiation therapy

Use our clinical trial search to find NCI-supported cancer clinical trials that are accepting patients. You can search for trials based on the type of cancer, the age of the patient, and where the trials are being done. General information about clinical trials is also available.

Sources: clinical trial search · General information

For patients · Treatment of Primary Adult Brain Tumor by Type of Tumor / Astrocytic Tumors

Pineal Astrocytic Tumors

Source: Adult Central Nervous System Tumors Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: January 5, 2024. Captured 2026-09-09.

Treatment of pineal astrocytic tumors may include surgery and radiation therapy. For high-grade tumors, chemotherapy may also be given.

Sources: pineal · astrocytic · radiation therapy · grade · chemotherapy

Use our clinical trial search to find NCI-supported cancer clinical trials that are accepting patients. You can search for trials based on the type of cancer, the age of the patient, and where the trials are being done. General information about clinical trials is also available.

Sources: clinical trial search · General information

For patients · Treatment of Primary Adult Brain Tumor by Type of Tumor / Astrocytic Tumors

Pilocytic Astrocytomas

Source: Adult Central Nervous System Tumors Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: January 5, 2024. Captured 2026-09-09.

Treatment of pilocytic astrocytomas may include surgery to remove the tumor. Radiation therapy may also be given if some of the tumor remains after surgery.

Sources: pilocytic · astrocytomas · Radiation therapy

Use our clinical trial search to find NCI-supported cancer clinical trials that are accepting patients. You can search for trials based on the type of cancer, the age of the patient, and where the trials are being done. General information about clinical trials is also available.

Sources: clinical trial search · General information

For patients · Treatment of Primary Adult Brain Tumor by Type of Tumor / Astrocytic Tumors

Diffuse Astrocytomas

Source: Adult Central Nervous System Tumors Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: January 5, 2024. Captured 2026-09-09.

Treatment of diffuse astrocytomas may include the following:

Sources: diffuse · astrocytomas

Surgery with or without radiation therapy.

Sources: radiation therapy

Surgery followed by radiation therapy and chemotherapy.

Sources: chemotherapy

Use our clinical trial search to find NCI-supported cancer clinical trials that are accepting patients. You can search for trials based on the type of cancer, the age of the patient, and where the trials are being done. General information about clinical trials is also available.

Sources: clinical trial search · General information

For patients · Treatment of Primary Adult Brain Tumor by Type of Tumor / Astrocytic Tumors

Anaplastic Astrocytomas

Source: Adult Central Nervous System Tumors Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: January 5, 2024. Captured 2026-09-09.

Treatment of anaplastic astrocytomas may include the following:

Sources: anaplastic · astrocytomas

Surgery and radiation therapy. Chemotherapy may also be given.

Sources: radiation therapy · Chemotherapy

Surgery and chemotherapy.

A clinical trial of chemotherapy placed into the brain during surgery.

Sources: clinical trial · brain

A clinical trial of a new treatment added to standard treatment.

Sources: standard treatment

Use our clinical trial search to find NCI-supported cancer clinical trials that are accepting patients. You can search for trials based on the type of cancer, the age of the patient, and where the trials are being done. General information about clinical trials is also available.

Sources: clinical trial search · General information

For patients · Treatment of Primary Adult Brain Tumor by Type of Tumor / Astrocytic Tumors

Glioblastomas

Source: Adult Central Nervous System Tumors Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: January 5, 2024. Captured 2026-09-09.

Treatment of glioblastomas may include the following:

Sources: glioblastomas

Surgery followed by radiation therapy and chemotherapy given at the same time, followed by chemotherapy alone.

Sources: radiation therapy · chemotherapy

Surgery followed by radiation therapy.

Chemotherapy placed into the brain during surgery.

Radiation therapy and chemotherapy given at the same time.

A clinical trial of a new treatment added to standard treatment.

Sources: clinical trial · standard treatment

Use our clinical trial search to find NCI-supported cancer clinical trials that are accepting patients. You can search for trials based on the type of cancer, the age of the patient, and where the trials are being done. General information about clinical trials is also available.

Sources: clinical trial search · General information

For patients · Treatment of Primary Adult Brain Tumor by Type of Tumor

Oligodendroglial Tumors

Source: Adult Central Nervous System Tumors Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: January 5, 2024. Captured 2026-09-09.

Treatment of oligodendrogliomas may include surgery with or without radiation therapy. Chemotherapy may be given after radiation therapy.

Sources: oligodendrogliomas · radiation therapy · Chemotherapy

Treatment of anaplastic oligodendroglioma may include the following:

Sources: anaplastic

Surgery followed by radiation therapy with or without chemotherapy.

A clinical trial of a new treatment added to standard treatment.

Sources: clinical trial · standard treatment

Use our clinical trial search to find NCI-supported cancer clinical trials that are accepting patients. You can search for trials based on the type of cancer, the age of the patient, and where the trials are being done. General information about clinical trials is also available.

Sources: clinical trial search · General information

For patients · Treatment of Primary Adult Brain Tumor by Type of Tumor

Mixed Gliomas

Source: Adult Central Nervous System Tumors Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: January 5, 2024. Captured 2026-09-09.

Treatment of mixed gliomas may include surgery and radiation therapy. Sometimes, chemotherapy is also given.

Sources: mixed gliomas · radiation therapy · chemotherapy

Use our clinical trial search to find NCI-supported cancer clinical trials that are accepting patients. You can search for trials based on the type of cancer, the age of the patient, and where the trials are being done. General information about clinical trials is also available.

Sources: clinical trial search · General information

For patients · Treatment of Primary Adult Brain Tumor by Type of Tumor

Ependymal Tumors

Source: Adult Central Nervous System Tumors Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: January 5, 2024. Captured 2026-09-09.

Treatment of grade I and grade II ependymomas may include surgery to remove the tumor. Radiation therapy may also be given if some of the tumor remains after surgery.

Sources: grade · ependymomas · Radiation therapy

Treatment of grade III anaplastic ependymoma may include surgery and radiation therapy.

Sources: anaplastic

Use our clinical trial search to find NCI-supported cancer clinical trials that are accepting patients. You can search for trials based on the type of cancer, the age of the patient, and where the trials are being done. General information about clinical trials is also available.

Sources: clinical trial search · General information

For patients · Treatment of Primary Adult Brain Tumor by Type of Tumor

Medulloblastomas

Source: Adult Central Nervous System Tumors Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: January 5, 2024. Captured 2026-09-09.

Treatment of medulloblastomas may include the following:

Sources: medulloblastomas

Surgery and radiation therapy to the brain and spine.

Sources: radiation therapy · spine

A clinical trial of chemotherapy added to surgery and radiation therapy to the brain and spine.

Sources: clinical trial · chemotherapy

Use our clinical trial search to find NCI-supported cancer clinical trials that are accepting patients. You can search for trials based on the type of cancer, the age of the patient, and where the trials are being done. General information about clinical trials is also available.

Sources: clinical trial search · General information

For patients · Treatment of Primary Adult Brain Tumor by Type of Tumor

Pineal Parenchymal Tumors

Source: Adult Central Nervous System Tumors Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: January 5, 2024. Captured 2026-09-09.

Treatment of pineal parenchymal tumors may include the following:

Sources: pineal · parenchymal

For pineocytomas, surgery and radiation therapy.

Sources: pineocytomas · radiation therapy

For pineoblastomas, surgery, radiation therapy, and chemotherapy.

Sources: chemotherapy

Use our clinical trial search to find NCI-supported cancer clinical trials that are accepting patients. You can search for trials based on the type of cancer, the age of the patient, and where the trials are being done. General information about clinical trials is also available.

Sources: clinical trial search · General information

For patients · Treatment of Primary Adult Brain Tumor by Type of Tumor

Meningeal Tumors

Source: Adult Central Nervous System Tumors Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: January 5, 2024. Captured 2026-09-09.

Treatment of grade I meningiomas may include the following:

Sources: grade · meningiomas

Active surveillance for tumors with no signs or symptoms.

Sources: Active surveillance · signs · symptoms

Surgery to remove the tumor. Radiation therapy may also be given if some of the tumor remains after surgery.

Sources: Radiation therapy

Stereotactic radiosurgery for tumors smaller than 3 centimeters.

Sources: Stereotactic radiosurgery · centimeters

Radiation therapy for tumors that cannot be removed by surgery.

Treatment of grade II and III meningiomas and hemangiopericytomas may include the following:

Sources: hemangiopericytomas

Surgery and radiation therapy.

Use our clinical trial search to find NCI-supported cancer clinical trials that are accepting patients. You can search for trials based on the type of cancer, the age of the patient, and where the trials are being done. General information about clinical trials is also available.

Sources: clinical trial search · General information

For patients · Treatment of Primary Adult Brain Tumor by Type of Tumor

Germ Cell Tumors

Source: Adult Central Nervous System Tumors Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: January 5, 2024. Captured 2026-09-09.

There is no standard treatment for germ cell tumors (germinoma, embryonal carcinoma, choriocarcinoma, and teratoma). Treatment depends on what the tumor cells look like under a microscope, the tumor markers, where the tumor is in the brain, and whether it can be removed by surgery.

Sources: standard treatment · germ cell tumors · carcinoma · choriocarcinoma · teratoma · tumor markers

Use our clinical trial search to find NCI-supported cancer clinical trials that are accepting patients. You can search for trials based on the type of cancer, the age of the patient, and where the trials are being done. General information about clinical trials is also available.

Sources: clinical trial search · General information

For patients · Treatment of Primary Adult Brain Tumor by Type of Tumor

Craniopharyngiomas

Source: Adult Central Nervous System Tumors Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: January 5, 2024. Captured 2026-09-09.

Treatment of craniopharyngiomas may include the following:

Sources: craniopharyngiomas

Surgery to completely remove the tumor.

Surgery to remove as much of the tumor as possible, followed by radiation therapy.

Sources: radiation therapy

Use our clinical trial search to find NCI-supported cancer clinical trials that are accepting patients. You can search for trials based on the type of cancer, the age of the patient, and where the trials are being done. General information about clinical trials is also available.

Sources: clinical trial search · General information

For patients

Treatment of Primary Adult Spinal Cord Tumors

Source: Adult Central Nervous System Tumors Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: January 5, 2024. Captured 2026-09-09.

For information about the treatments listed below, see the Treatment Option Overview section.

Sources: Treatment Option Overview

Treatment of spinal cord tumors may include the following:

Sources: spinal cord

Surgery to remove the tumor.

Radiation therapy.

Sources: Radiation therapy

A clinical trial of a new treatment.

Sources: clinical trial

For patients

Treatment of Recurrent Adult Central Nervous System Tumors

Source: Adult Central Nervous System Tumors Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: January 5, 2024. Captured 2026-09-09.

For information about the treatments listed below, see the Treatment Option Overview section.

Sources: Treatment Option Overview

There is no standard treatment for recurrent central nervous system (CNS) tumors. Treatment depends on the patient's condition, the expected side effects of the treatment, where the tumor is in the CNS, and whether the tumor can be removed by surgery. Treatment may include the following:

Sources: standard treatment · recurrent · central nervous system (CNS) tumors · side effects

Chemotherapy placed into the brain during surgery.

Sources: Chemotherapy · brain

Chemotherapy with drugs not used to treat the original tumor.

Targeted therapy for recurrent glioblastoma.

Sources: Targeted therapy · glioblastoma

Radiation therapy.

Sources: Radiation therapy

Surgery to remove the tumor.

A clinical trial of a new treatment.

Sources: clinical trial

Use our clinical trial search to find NCI-supported cancer clinical trials that are accepting patients. You can search for trials based on the type of cancer, the age of the patient, and where the trials are being done. General information about clinical trials is also available.

Sources: clinical trial search · General information

For patients

Treatment of Metastatic Adult Brain Tumors

Source: Adult Central Nervous System Tumors Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: January 5, 2024. Captured 2026-09-09.

For information about the treatments listed below, see the Treatment Option Overview section.

Sources: Treatment Option Overview

Treatment of one to four tumors that have spread to the brain from another part of the body may include the following:

Sources: brain

Radiation therapy to the whole brain with or without surgery.

Sources: Radiation therapy

Radiation therapy to the whole brain with or without stereotactic radiosurgery.

Sources: stereotactic radiosurgery

Stereotactic radiosurgery.

Chemotherapy, if the primary tumor is one that responds to anticancer drugs. It may be combined with radiation therapy.

Sources: Chemotherapy · primary tumor · anticancer

Treatment of tumors that have spread to the leptomeninges may include the following:

Sources: leptomeninges

Chemotherapy (systemic and/or intrathecal). Radiation therapy may also be given.

Sources: systemic · intrathecal

Supportive care.

Sources: Supportive care

Use our clinical trial search to find NCI-supported cancer clinical trials that are accepting patients. You can search for trials based on the type of cancer, the age of the patient, and where the trials are being done. General information about clinical trials is also available.

Sources: clinical trial search · General information

Studies

Radiation Therapy With or Without Chemotherapy in Treating Patients With Anaplastic Oligodendroglioma

NCT00002569 · COMPLETED · phase3

Brain and Central Nervous System Tumors

ClinicalTrials.gov record

Radiation Therapy With or Without Radiosurgery in Treating Patients With Brain Metastases

NCT00002708 · COMPLETED · phase3

Metastatic Cancer

ClinicalTrials.gov record

Radiation Therapy With and Without Combination Chemotherapy in Patients With Resected Anaplastic Oligodendroglioma

NCT00002840 · COMPLETED · phase3

Brain and Central Nervous System Tumors

ClinicalTrials.gov record

Observation or Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Low-Grade Glioma

NCT00003375 · COMPLETED · phase2, phase3

Brain and Central Nervous System Tumors

ClinicalTrials.gov record

Radiation Therapy With or Without Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

NCT00006353 · COMPLETED · phase3

Brain and Central Nervous System Tumors

ClinicalTrials.gov record

Radiation Therapy or Temozolomide in Treating Patients With Gliomas

NCT00182819 · COMPLETED · phase3

Brain and Central Nervous System Tumors

ClinicalTrials.gov record

Radiation Therapy (RT) and Temozolomide (TMZ) in Treating Patients With Newly Diagnosed Glioblastoma or Gliosarcoma

NCT00304031 · COMPLETED · phase3

Brain and Central Nervous System Tumors

ClinicalTrials.gov record

A Study to Evaluate Bevacizumab Alone or in Combination With Irinotecan for Treatment of Glioblastoma Multiforme (BRAIN)

NCT00345163 · COMPLETED · phase2

Glioblastoma

ClinicalTrials.gov record

Everolimus (RAD001) Therapy of Giant Cell Astrocytoma in Patients With Tuberous Sclerosis Complex

NCT00411619 · COMPLETED · phase1, phase2

Tuberous Sclerosis, Subependymal Giant Cell Astrocytoma

ClinicalTrials.gov record

Phase III Trial of Anaplastic Glioma Without 1p/19q Loss of Heterozygosity (LOH)

NCT00626990 · ACTIVE NOT RECRUITING · phase3

Brain and Central Nervous System Tumors

ClinicalTrials.gov record

Efficacy and Safety of Everolimus (RAD001) in Patients of All Ages With Subependymal Giant Cell Astrocytoma Associated With Tuberous Sclerosis Complex (TSC)(EXIST-1)

NCT00789828 · COMPLETED · phase3

Tuberous Sclerosis, Subependymal Giant Cell Astrocytoma

ClinicalTrials.gov record

Temozolomide and Radiation Therapy With or Without Bevacizumab in Treating Patients With Newly Diagnosed Glioblastoma

NCT00884741 · COMPLETED · phase3

Glioblastoma, Gliosarcoma, Supratentorial Glioblastoma

ClinicalTrials.gov record

Radiation Therapy With Concomitant and Adjuvant Temozolomide Versus Radiation Therapy With Adjuvant PCV Chemotherapy in Patients With Anaplastic Glioma or Low Grade Glioma

NCT00887146 · ACTIVE NOT RECRUITING · phase3

Brain and Central Nervous System Tumors

ClinicalTrials.gov record

A Study of Bevacizumab (Avastin®) in Combination With Temozolomide and Radiotherapy in Participants With Newly Diagnosed Glioblastoma

NCT00943826 · COMPLETED · phase3

Glioblastoma

ClinicalTrials.gov record

Bevacizumab and Lomustine for Recurrent GBM

NCT01290939 · COMPLETED · phase3

Glioblastoma Multiforme, Cognition Disorders, Disability Evaluation

ClinicalTrials.gov record

Oral ONC201 in Adult Recurrent Glioblastoma

NCT02525692 · TERMINATED · phase2

Glioblastoma, Diffuse Midline Glioma, H3 K27M Glioma, Thalamic Glioma, Infratentorial Glioma, Basal Ganglia Glioma

ClinicalTrials.gov record

Expanded Access to ONC201 for Patients With H3 K27M-mutant and/or Midline High Grade Gliomas

NCT03134131 · NO LONGER AVAILABLE · Phase not reported

Glioma

ClinicalTrials.gov record

A Study of Pomalidomide Monotherapy for Children and Young Adults With Recurrent or Progressive Primary Brain Tumors

NCT03257631 · COMPLETED · phase2

Central Nervous System Neoplasms, Medulloblastoma

ClinicalTrials.gov record

Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Relapsed Germ Cell Cancer

NCT00002931 · COMPLETED · phase2

Brain and Central Nervous System Tumors, Extragonadal Germ Cell Tumor, Ovarian Cancer, Teratoma, Testicular Germ Cell Tumor

ClinicalTrials.gov record

Antineoplaston Therapy in Treating Patients With Brain Tumors

NCT00003457 · COMPLETED · phase2

Refractory Brain Tumors

ClinicalTrials.gov record

Combination Chemotherapy, Monoclonal Antibody, and Radiation Therapy in Treating Patients With Primary Central Nervous System Lymphoma

NCT00068250 · COMPLETED · phase1, phase2

Brain and Central Nervous System Tumors, Lymphoma

ClinicalTrials.gov record

Treating Patients With Recurrent PCNSL With Carboplatin/BBBD and Adding Rituxan To The Treatment Regimen

NCT00074165 · TERMINATED · phase2

Brain and Central Nervous System Tumors, Drug/Agent Toxicity by Tissue/Organ, Lymphoma, Thrombocytopenia

ClinicalTrials.gov record

Erlotinib and Temsirolimus in Treating Patients With Recurrent Malignant Glioma

NCT00112736 · COMPLETED · phase1, phase2

Adult Anaplastic Astrocytoma, Adult Anaplastic Oligodendroglioma, Adult Diffuse Astrocytoma, Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Adult Mixed...

ClinicalTrials.gov record

Temozolomide in Treating Patients With Low-Grade Glioma

NCT00313729 · COMPLETED · phase2

CNS Tumor, Adult

ClinicalTrials.gov record

Donepezil in Treating Patients Who Have Undergone Radiation Therapy for Brain Tumors

NCT00369785 · COMPLETED · phase3

Brain Tumors, Metastatic Disease

ClinicalTrials.gov record

Paclitaxel, Ifosfamide, and Carboplatin Followed By Autologous Stem Cell Transplant in Treating Patients With Germ Cell Tumors That Did Not Respond to Cisplatin

NCT00423852 · COMPLETED · phase1, phase2

Brain and Central Nervous System Tumors, Extragonadal Germ Cell Tumor, Ovarian Cancer, Teratoma, Testicular Germ Cell Tumor

ClinicalTrials.gov record

Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer

NCT00445965 · COMPLETED · phase2

Brain and Central Nervous System Tumors, Intraocular Melanoma, Lung Cancer, Melanoma (Skin), Metastatic Cancer, Neuroblastoma, Ovarian Cancer, Retinoblastoma, Sarcoma, Small...

ClinicalTrials.gov record

Combination Chemotherapy and Pegfilgrastim in Treating Patients With Previously Untreated Germ Cell Tumors

NCT00470366 · COMPLETED · phase2

Brain and Central Nervous System Tumors, Extragonadal Germ Cell Tumor, Ovarian Cancer, Teratoma, Testicular Germ Cell Tumor

ClinicalTrials.gov record

Temozolomide in Treating Patients With Recurrent Glioblastoma Multiforme or Other Malignant Glioma

NCT00498927 · COMPLETED · phase2

Brain and Central Nervous System Tumors

ClinicalTrials.gov record

Everolimus, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma

NCT00553150 · COMPLETED · phase1, phase2

Brain and Central Nervous System Tumors

ClinicalTrials.gov record

Rosiglitazone in Treating Patients With Pituitary Tumors

NCT00616642 · TERMINATED · phase2

Brain and Central Nervous System Tumors

ClinicalTrials.gov record

Opioid Titration Order Sheet or Standard Care in Treating Patients With Cancer Pain

NCT00666211 · COMPLETED · phase3

Brain and Central Nervous System Tumors, Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Lymphoproliferative Disorder, Multiple Myeloma and Plasma Cell Neoplasm,...

ClinicalTrials.gov record

Methadone, Morphine, or Oxycodone in Treating Pain in Patients With Cancer

NCT00726830 · TERMINATED · na

Brain and Central Nervous System Tumors, Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Lymphoproliferative Disorder, Multiple Myeloma and Plasma Cell Neoplasm,...

ClinicalTrials.gov record

Armodafinil in Treating Fatigue Caused By Radiation Therapy in Patients With Primary Brain Tumors

NCT01032200 · COMPLETED · phase2

Brain Tumors, Nervous System Tumors, Cognition Disorders, Fatigue

ClinicalTrials.gov record

Photodynamic Therapy (PDT) For Recurrent High Grade Gliomas

NCT01966809 · TERMINATED · phase2

Brain Tumor, Recurrent

ClinicalTrials.gov record

18F-FDOPA PET/CT or PET/MRI in Measuring Tumors in Patients With Newly-Diagnosed or Recurrent Gliomas

NCT02175745 · TERMINATED · na

Adult Anaplastic Ependymoma, Adult Anaplastic Oligodendroglioma, Adult Brain Stem Glioma, Adult Diffuse Astrocytoma, Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult...

ClinicalTrials.gov record

Alisertib and Fractionated Stereotactic Radiosurgery in Treating Patients With Recurrent High Grade Gliomas

NCT02186509 · COMPLETED · phase1

Adult Anaplastic Astrocytoma, Adult Anaplastic Ependymoma, Adult Anaplastic Oligodendroglioma, Adult Brain Stem Glioma, Adult Diffuse Astrocytoma, Adult Giant Cell...

ClinicalTrials.gov record

Study of Binimetinib With Encorafenib in Adults With Recurrent BRAF V600-Mutated HGG

NCT03973918 · TERMINATED · phase2

High Grade Glioma, BRAF V600E, BRAF V600K, Anaplastic Astrocytoma, Anaplastic Pleomorphic Xanthoastrocytoma, Gliosarcoma, Glioblastoma

ClinicalTrials.gov record

Disease and treatment settings

Adult Brain Glioblastoma

Disease and treatment setting

Adult Brain Glioblastoma

Adult Giant Cell Glioblastoma

Disease and treatment setting

Adult Giant Cell Glioblastoma

Adult Gliosarcoma

Disease and treatment setting

Adult Gliosarcoma

Angiocentric Glioma

Disease and treatment setting

Angiocentric Glioma

Central Nervous System Tumors

Disease and treatment setting

Central Nervous System Tumors

Diffuse Midline Glioma, H3 K27M-Mutant

Disease and treatment setting

Diffuse Midline Glioma, H3 K27M-Mutant

Gliosarcoma

Disease and treatment setting

Gliosarcoma

localized Central Nervous System Tumors

Disease and treatment setting

Localized chemotherapy (carmustine wafer)

metastatic Central Nervous System Tumors

Disease and treatment setting

Treatment of Metastatic Brain Tumors

Pilocytic Astrocytoma

Disease and treatment setting

Pilocytic Astrocytoma

recurrent Central Nervous System Tumors

Disease and treatment setting

Treatment of Recurrent CNS Tumors

Supratentorial Glioblastoma

Disease and treatment setting

Supratentorial Glioblastoma

Drug labels

FeraBright

Label date 2025-10-14

FERABRIGHT is indicated for magnetic resonance imaging (MRI) of the brain in adults with known or suspected malignant neoplasms in the brain to visualize lesions with a disrupted blood-brain barrier. FERABRIGHT is an iron-based contrast...

DailyMed label

GLEOLAN

Label date 2026-01-29

Gleolan is indicated in patients with glioma [suspected World Health Organization (WHO) Grades III or IV on preoperative imaging] as an adjunct for the visualization of malignant tissue during surgery. Gleolan is an optical imaging...

DailyMed label

Gleostine

Label date 2024-01-23

Gleostine is an alkylating drug indicated for the treatment of patients with: Brain tumors, primary and metastatic, following appropriate surgical and/or radiotherapeutic procedures. ( 1 ) Hodgkin's lymphoma in combination with other...

DailyMed label

Gleostine

Label date 2025-09-25

Gleostine is an alkylating drug indicated for the treatment of patients with: Brain tumors, primary and metastatic, following appropriate surgical and/or radiotherapeutic procedures. ( 1 ) Hodgkin's lymphoma in combination with other...

DailyMed label

Gliadel

Label date 2024-12-05

GLIADEL Wafer is indicated for the treatment of patients with: newly-diagnosed high-grade glioma as an adjunct to surgery and radiation, and recurrent glioblastoma as an adjunct to surgery. GLIADEL Wafer is an alkylating drug indicated...

DailyMed label

Lomustine

Label date 2026-02-12

Lomustine is an alkylating drug indicated for the treatment of patients with: Brain tumors, primary and metastatic, following appropriate surgical and/or radiotherapeutic procedures. ( 1 ) Hodgkin's lymphoma in combination with other...

DailyMed label

MODEYSO

Label date 2026-01-09

MODEYSO is indicated for the treatment of adult and pediatric patients 1 year of age and older with diffuse midline glioma harboring an H3 K27M mutation with progressive disease following prior therapy. This indication is approved under...

DailyMed label

TEMODAR

Label date 2026-02-20

TEMODAR is an alkylating drug indicated for the treatment of adults with: Newly diagnosed glioblastoma concomitantly with radiotherapy and then as maintenance treatment. ( 1.1 ) Anaplastic astrocytoma. ( 1.2 ) Adjuvant treatment of...

DailyMed label